

1 **Title:** Core circadian clock transcription factor BMAL1 regulates mammary epithelial cell
2 growth, differentiation, and milk component synthesis.

3 **Authors:** Theresa Casey^{1†}, Aridany Suarez-Trujillo¹, Shelby Cummings¹, Katelyn Huff¹,
4 Jennifer Crodian¹, Ketaki Bhide², Clare Aduwari¹, Kelsey Teeple¹, Avi Shamay³, Sameer J.
5 Mabjeesh⁴, Phillip San Miguel⁵, Jyothi Thimmapuram², and Karen Plaut¹

6 **Affiliations:** 1. Department of Animal Science, Purdue University, West Lafayette, IN, USA; 2.
7 Bioinformatics Core, Purdue University; 3. Animal Science Institute, Agriculture Research
8 Origination, The Volcani Center, Rishon Letsiyon, Israel. 4. Department of Animal Sciences,
9 The Robert H. Smith Faculty of Agriculture, Food, and Environment, The Hebrew University of
10 Jerusalem, Rehovot, Israel. 5. Genomics Core, Purdue University

11 **Grant support:** Binational Agricultural Research Development (BARD) Research Project US-
12 4715-14; Photoperiod effects on milk production in goats: Are they mediated by the molecular
13 clock in the mammary gland?

14 **†Address for correspondence.**

15 Theresa M. Casey
16 BCHM Room 326
17 175 South University St.
18 West Lafayette, IN 47907
19 Email: theresa-casey@purdue.edu
20 Phone: 802-373-1319
21
22

23 **ABSTRACT**

24 The role the mammary epithelial circadian clock plays in gland development and lactation is
25 unknown. We hypothesized that mammary epithelial clocks function to regulate mammogenesis
26 and lactogenesis, and propose the core clock transcription factor BMAL1:CLOCK regulates
27 genes that control mammary epithelial development and milk synthesis. Our objective was to
28 identify transcriptional targets of BMAL1 in undifferentiated (UNDIFF) and lactogen
29 differentiated (DIFF) mammary epithelial cells (HC11) using ChIP-seq. Ensembl gene IDs with
30 the nearest transcriptional start site to peaks were explored as potential targets, and represented
31 846 protein coding genes common to UNDIFF and DIFF cells and 2773 unique to DIFF samples.
32 Genes with overlapping peaks between samples (1343) enriched cell-cell adhesion, membrane
33 transporters and lipid metabolism categories. To functionally verify targets, an HC11 line with
34 *Bmall* gene knocked out (BMAL1-KO) using CRISPR-CAS was created. BMAL1-KO cultures
35 had lower cell densities over an eight-day growth curve, which was associated with increased
36 (p<0.05) levels of reactive oxygen species and lower expression of superoxide dismutase 3
37 (*Sod3*). Q-PCR analysis also found lower expression of the putative targets, prolactin receptor
38 (*Prlr*), *Ppara*, and beta-casein (*Csn2*). Findings support our hypothesis and highlight potential
39 importance of clock in mammary development and substrate transport.

40

41

42

43

44

45

46 **INTRODUCTION**

47 Circadian clocks set daily rhythms of gene expression to maintain tissue homeostasis and
48 coordinate cellular metabolism[1-3]. In mammary tissue, temporal expression patterns of core
49 clock genes change across reproductive states of the female, and appear to be associated with
50 changes in developmental stage of the gland [4, 5]. However, the significance of these changes
51 and the role of the molecular clock and core clock genes' functions in mammary development
52 and lactation is currently unknown.

53 Clocks' molecular mechanism generate circadian rhythms through a series of interlocked
54 transcription-translation feedback loops. CLOCK and BMAL1 are at the core of the loop, and as
55 a heterodimer (BMAL1:CLOCK) function as a transcription factor that binds the enhancer box
56 (E-box) regulatory element in promoter regions of genes[6]. *Period* (*Per1*, *Per2* and *Per3*) and
57 *Cryptochrome* (*Cry1* and *Cry2*) genes are transcriptional targets of BMAL1:CLOCK and form
58 the negative arm of the core circadian clock loop, whereby PER and CRY proteins together
59 inhibit CLOCK:BMAL1-mediated transcription[7-10]. The 24 hr periodicity in activation-
60 repression of elements of the core molecular clock results in corresponding circadian rhythms of
61 gene expression in about 10% of the transcriptome[8].

62 Although there is some overlap, the rhythmic output genes of clocks differ among tissues,
63 allowing circadian control of function and activity appropriate for each organ. Circadian and cell
64 cycle regulation is coupled to coordinate cell proliferation with tissue function across multiple
65 organs[8, 11, 12]. This coupling likely also exists in the mammary gland, as temporal analysis of
66 mammary transcriptomes of mature virgin mice[13] and lactating women[14] demonstrated
67 genes that regulate cell growth and differentiation exhibit circadian rhythms of expression.
68 Moreover, the *Clock-Δ19* mice, which have a point mutation that results in down regulation of

69 CLOCK-BMAL1 target genes, exhibit decreased lactation competence as evident in lower rates
70 of pup growth and increased rates of neonatal mortality[15-17]. The decreased postnatal pup
71 survival was associated with impaired mammary development in *Clock-Δ19* dams[18], and
72 isolated mammary epithelial cells from virgin *Clock-Δ19* mice had lower stem cell-like
73 properties[13]. Whereas reduction of CLOCK protein in a mammary epithelial cell line with
74 shRNA affected cell growth and decreased expression of factors associated with mammary
75 differentiation and milk synthesis[18].

76 With this knowledge, we hypothesized that circadian clocks in the mammary gland play
77 an integral role in regulating mammogenesis. In particular, we proposed that the transcription
78 factor BMAL1:CLOCK functions to regulate expression of genes that control mammary
79 epithelial development. Moreover, the observation that stoichiometry changed between positive
80 (BMAL:CLOCK) and negative (PER2) elements of core circadian clock components in the
81 mammary gland during the transition from pregnancy to lactation [5] led us to the hypothesize
82 that transcriptional targets of BMAL1:CLOCK change as the gland differentiates and function to
83 regulate milk component synthesis. The objectives of this study were to use ChIP-seq analysis to
84 identify transcriptional targets of BMAL1, and determine if targets of BMAL1 changed upon
85 differentiation of mammary epithelial cells. A line of mammary epithelial cells with the BMAL1
86 gene knocked out (BMAL1-KO) using CRISPR-CAS was created to verify ChIP-seq findings,
87 and study functional effects of loss of gene on growth and differentiation of cells in culture.

88 RESULTS

89 ***Validation of BMAL1 antibody and quality of ChIP-seq data.*** To test the hypothesis that
90 BMAL1 transcriptional targets changed with state of mammary epithelial differentiation we used
91 ChIP-seq analysis to identify genes potentially regulated by BMAL1 in undifferentiated

92 (UNDIFF) and lactogen hormone differentiated (DIFF) HC11 cultures. Prior to beginning
93 studies, specificity of the ChIP-grade antibody for the BMAL1 protein was confirmed with
94 immunoprecipitation and western blot analysis (Supplemental Figure S1a). Nanochip analysis of
95 sonicated input DNA indicated that optimal size of sheared fragments was achieved for ChIP-seq
96 analysis (Supplemental Figure S1b). Evaluation of antibody specificity indicated no difference
97 between mock-ChIP and BMAL1-ChIP samples in the cycle threshold values following q-PCR
98 analysis of an exon region of the *Mageal_2* sperm specific gene, which is not a
99 BMAL1:CLOCK target. Whereas a 9-fold difference in enrichment was found between q-PCR
100 product of BMAL1-ChIP and mock-ChIP for the *Per1* promoter region versus the exon region of
101 *Mageal_2* (Supplemental Figure S1c).

102 **Supplemental Figure S1.** (a) Western blot analysis of immunoprecipitation (IP) of BMAL1
103 protein in HC11 cell protein lysate using rabbit polyclonal antibody to BMAL1 (ab3350, ChIP
104 grade, 2 µg per IP). Lane 1 = Precision Plus Protein Standard Ladder; Lane 2= 100 µg, Lane 3= 105
150 µg, Lane 4 = 200 µg, Lane 5= 200 µg of lysate precleared and incubated with beads but no
106 Ab (-), Lane 6= an aliquot of supernatant pulled off of lane 5 sample before wash steps that
107 precede elution. western blot was performed using the mouse monoclonal antibody to BMAL 1
108 (sc-373955 @ 1:750 primary antibody concentration) for visualization. (b) Electropherogram
109 analysis of input DNA used for ChIP-seq shows ideal size for next generation sequencing (seq).
110 (c) Evaluation of antibody specificity indicated no difference between mock-ChIP and BMAL1-
111 ChIP samples in the cycle threshold values following q-PCR analysis of an exon region of the
112 *Mageal_2* sperm specific gene, which is not a BMAL1:CLOCK target. Whereas a 9-fold
113 difference in enrichment was found between q-PCR analysis of BMAL1-ChIP and mock-ChIP
114 for the *Per1* promoter region versus the exon region of *Mageal_2*. To calculate relative amount
115 of input target brought down by ChIP with BMAL1 antibody the following equation was use:
116 adjusted input sample-C_T of ChIP sample. A positive ChIP was defined as at least 2-fold greater
117 than mock-IP sample.

118 The eight samples sequenced for these studies consisted of four pairs of input and ChIP
119 samples with two pairs from UNDIFF and two from DIFF HC11 cultures. Across the four
120 samples the amount of DNA captured by ChIP was $1.03 \pm 0.24\%$ of the input DNA. Mapping
121 rate of reads to the mouse genome across the four paired input-ChIP samples averaged 96%
122 (Supplemental Table S1). For UNDIFF samples, there was an average of ~6,000 peaks with a 2-

123 fold enrichment over input tag count (FDR ≤ 0.01), and over 13,000 peaks were identified across
124 both DIFF samples. Annotation analysis of peaks found similar frequencies of location within
125 the genome across the samples, with approximately 62% of peaks located in intergenic sites and
126 34% within introns (Figure 1a). Less than 1% of peaks were found in 3' untranslated region,
127 transcriptional termination sites (TSS), and within exons.

128 **Figure 1.** (a) Homer annotation analysis of BMAL1 ChIP-seq peak location shows frequency of
129 distribution across the genome in undifferentiated (UNDIFF) and lactogen differentiated (DIFF)
130 HC11 cultures. 3UTR, 3' untranslated region; TTS, terminal transcription site; pseudo,
131 pseudogene; 5UTR, 5' untranslated region. (b) Venn diagram illustrating the overlap and number
132 of unique Ensembl gene IDs of protein coding genes with transcriptional start site nearest to
133 BMAL1 ChIP-seq peaks in the two undifferentiated (UNDIFF1 and UNDIFF2) and two
134 differentiated (DIFF1 and DIFF2) samples.
135

136 ***Functional analysis of protein coding genes nearest transcriptional start sites of ChIP-seq***
137 ***peaks.*** Ensembl protein coding gene IDs with the nearest transcriptional start site to peaks were
138 explored as potential regulatory targets of BMAL1. Analysis of overlapping gene IDs among the
139 samples found 846 common to all four ChIPed samples (i.e. UNDIFF and DIFF; Figure 1b;
140 Supplemental Table S2). There were 2773 protein coding genes common to both DIFF samples,
141 but not found in UNDIFF samples, and were considered as potential BMAL1 targets distinctly
142 regulated in differentiated versus undifferentiated mammary epithelial cells (Supplemental Table
143 S3). Potential BMAL1 target genes with overlapping peaks between at least two samples were
144 considered high confidence and used for downstream analysis. There were 97 common between
145 UNDIFF samples (Supplemental Table S4) and 778 common between DIFF samples
146 (Supplemental Table S5). Gene targets with overlapping peaks between any two samples (1343;
147 Supplemental Table S6), regardless of differentiation state, were used for downstream analysis.

148 Functional annotation analysis of the 1343 genes with overlapping peaks (Table 1;
149 Supplemental Table S7) found approximately one-third enriched the gene ontology *membrane*.

150 Among the genes in this category were nine glutamate receptors, ten solute carriers, the Wnt
151 receptor *Fzd1* and receptors for prolactin, growth hormone, insulin and parathyroid hormone.
152 Within the category GO:0007156~*homophilic cell adhesion via plasma membrane adhesion*
153 *molecules* were fourteen cadherin genes and three atypical cadherins. Also among the BMAL1
154 targets were genes that encoded multiple ephrin receptors and their ligands, prostaglandin E
155 receptors, mitochondrial fission regulators, cell division regulators, multiple steroid hormone
156 receptors and extracellular matrix proteins and proteases (Table 1).

157

158 Ingenuity Pathway Analysis (IPA) tools were used to further explore the data set of

Table 1. Representative categories enriched with protein coding genes nearest to BMAL1 ChIP-seq overlapping peaks

| Term | Count | Percent | p-value | Representative genes within category |
|--|-------|---------|----------|--|
| GO:0016020~membrane | 449 | 33.46 | 9.29E-08 | adhesion G protein-coupled receptors [Adgrb3, Adgre5, Adgrl2, Adgrl3], glutamate receptor ionotropic [Grin2a, Grin3a, Gria1, Gria2, Gria3, Grid2], glutamate receptor, metabotropic [Grm3, Grm7, Grm8], parathyroid hormone 2 receptor[Pth2r], prolactin receptor[Prlr], insulin receptor[Insr], growth hormone receptor [Ghr], frizzled class receptor 1[Fzd1], solute carrier family [Slc10a2, Slc13a1, Slc20a2, Slc30a8, Slc38a10, Slc38a4, Slc39a11, Slc39a10, Slc4a4, Slc8a1] |
| GO:0007156~ <i>homophilic cell adhesion via plasma membrane adhesion molecules</i> | 26 | 1.93 | 1.41E-06 | Cadherins [Cdh4, Cdh5, Cdh6, Cdh7, Cdh8, Cdh9, Cdh10, Cdh11, Cdh12, Cdh13, Cdh17, Cdh18, Cdh19, Cdh20]; protocadherin [Pcdh18, Pcdh19] Atypical cadherins [Fat1, Fat3, Fat4] |
| GO:0004957~prostaglandin E receptor activity | 4 | 0.30 | 1.34E-03 | Ptger2, Ptger3, Ptger4 |
| GO:0048013~ephrin receptor signaling pathway | 9 | 0.67 | 1.61E-03 | Eph receptors [Epha3, Epha5, Epha6, Epha7], ephrins [Efna3, Efna5, Efnb2] |
| GO:0006813~potassium ion transport | 16 | 1.19 | 2.79E-03 | Kcnab1, Kcnb2, Kcnd2, Kcnd3, Keng3, Kcnj16, Kcnj2, Kcnk1, Kcnk2, Kcnmb2, Kcnq3, Kcnq5, Kcns2, Kcnv1 |
| GO:0004842~ubiquitin-protein transferase activity | 30 | 2.24 | 4.18E-03 | tripartite motif-containing [Trim2, Trim24, Trim32, Trim56], ring finger protein [Rnf19a, Rnf216], Genes involved in cellular response to DNA damage [BRCA1 associated RING domain 1(Bard1), F-box and WD-40 domain protein 7(Fbxw7), NSE2/MMS21 homolog, SMC5-SMC6 complex SUMO ligase(Nsmce2), ubiquitin protein ligase E3 component n-recognin 5(Ubr5), ubiquitin-conjugating enzyme E2E 2(Ube2e2), ubiquitin-conjugating enzyme E2W (Ube2w)] |
| GO:0043565~sequence-specific DNA binding | 47 | 3.50 | 1.69E-02 | homeobox genes [Irx3, Nkx6-1, Nobox, Pou4f2, Cux1, Isx, Obox2, Prrx1, Pbx1, Satb1, Satb2, Zfhx3], steroid hormone receptor [Esrrg, Hnf4g, Nr3c2, Nr5a2, Rarb, Thrb] |
| GO:0009115~xanthine catabolic process | 3 | 0.22 | 2.49E-02 | aldehyde oxidases [Aox1, Aox2, Aox3] |
| GO:0031012~extracellular matrix | 24 | 1.79 | 3.89E-02 | proteases [Adams5, Adams12, Adams18, Adams20, MMp16], collagens [Col1a2, Col3a1, Col5a2, Col8a1, Col11a1], Postn, Fbn2, Nid2, Thbs2 |
| GO:0000266~mitochondrial fission | 3 | 0.22 | -- | ganglioside-induced differentiation-associated-protein 1 [Gdap1], fission, mitochondrial 1 [Fis1], dynamin 1-like [Dnm1] |
| GO:0051301~cell division | 25 | 1.8 | -- | Cdc14a, Centromere proteins [Cenpc1, Cenpe, Cenpw], Cyclin dependent kinases [Cdk6, Cdk14], par-3 family cell polarity regulator [Pard3, Pad3b] |
| GO:0006629~lipid metabolic process | 24 | 1.7 | -- | Lipid biosynthesis [Agpat9, Mid1ip1, Gpam, Oxsm, Cbr4, Cyp51, Lclat, Lpgat], lipid degradation [Daglb, Enpp2, Galc, Lpl, Pnpla6, Plcd3, Pla2g4a], cholesterol metabolism [Vldlr, Lep, Cyp7b1] |

159 potential BMAL1 targets represented by overlapping peaks between samples. The most enriched

160 IPA canonical pathway was *Synaptogenesis Signaling Pathway* ($p=1.21\text{E-}10$; Supplemental
161 Table S8). Among the 43 genes that enriched this pathway were fourteen cadherins, ephrins and
162 their receptors, glutamate receptors, the very low density lipoprotein receptor (*Vldr*), and alpha
163 synuclein (*Snca*). Another highly enriched canonical pathway was *Axonal Guidance Signaling*
164 ($p\text{-value}=4.67\text{E-}6$; Supplemental Table S9). Genes that enriched this pathway included two
165 round about guidance receptors (*Robo1*, *Robo2*) and their ligand (*Slit2*), semaphorins (Sema3A,
166 Sema5A), *Wnt2*, *Wnt2b*, unc-5 netrin receptors (*Unc5c*, *Unc5d*) and netrin G (*Ntng1*). IPA
167 identified the glutamate receptor GRIN3A ($p\text{-value}=1.05\text{ E-}16$; Supplemental Table S10), the
168 CREB transcription factor ($p\text{-value}=2.76\text{ E-}14$; Supplemental Table S11), and the chorionic
169 gonadotropin complex (CG; $p\text{-value}=2.28\text{ E-}8$; Supplemental Table S12) as among the most
170 significant upstream regulators of BMAL1 target genes, with 32, 72 and 45 molecules in the
171 datasets, respectively. The IPA generated regulator network with the highest consistency score
172 indicated the potential BMAL1 targets positively affected processes involved in formation of
173 cellular protrusions, branching of cells, development of sensory organ, sprouting, size of body,
174 and efflux of lipids, while inhibiting organismal death (Supplemental Table 13; Supplemental
175 Figure S2.) A schematic, which represented approximately 15% of the BMAL1 targets, was
176 generated using IPA my pathway tools by combining genes identified as downstream targets of
177 CREB and estradiol (Figure 2; Supplemental Table 14). The schematic illustrates that BMAL1
178 targets encode proteins across multiple subcellular locations, and the presence of multiple ligand
179 and receptor pairs to include prolactin (*Prl8a2*) and its receptor (*Prlr*), *Slit2* and *Robo*, *Wnt2* and
180 *Fzdl*, glial cell derived neurotrophic factor (*Gdnf*) and its receptor (*Gfra1*) and insulin (*Ins1*) and
181 its receptor (*Insr*).

182 **Supplemental Figure S2.** Ingenuity pathway analysis generated network with greatest
183 consistency score reflecting relationships between BMAL1 targets and predicted downstream

184 effects. Gene names and symbols are defined in Supplemental Table S13. The predicted
185 upstream regulators were removed, as analysis assumes this is BMAL1 as the transcriptional
186 regulator of genes in red and combined the downstream effects of inhibiting organismal death,
187 and stimulating efflux of lipids, cellular protrusions, branching of cells, development of sensory
188 organ, sprouting and organ size.

189 **Figure 2.** Schematic showing cellular location of BMAL1 targets downstream of CREB1 and
190 estradiol generated using Ingenuity Pathway Analysis tools, with the addition of insulin and Fzd1
191 genes. Gene names and symbols are given here and can be found with more detail in
192 Supplemental Table S14. ATP-binding cassette subfamily A (Abca1, Abca8a, Abcg2); Activin A
193 receptor (Acvr2a), ADAM metallopeptidase with thrombospondin type 1 (Adamts5, 18) and
194 ADAM like decysin (Adamdec1), angiotensin II receptor (Agtr1b), A kinase anchoring protein
195 (Akap9,13), angiopoietin (Angpt1), inorganic phosphate transporter (Ankh), amyloid beta
196 precursor protein (APP), bone morphogenetic protein receptor type 1B (Bmpr1b), bisphosphate
197 nucleotidase (Bpnt2) retinoic acid inducible (Brinp2), chromosome 2 open reading frame 88
198 (C2orf88), serum/glucocorticoid regulated kinase (Sgk3), calcium dependent secretion activator
199 2 (Cadps2), cellular communication network factor 3 (Ccn3), cadherins (Cdh8, 10,11, 13), cyclin
200 dependent kinase (Cdk6, 14), CF transmembrane conductance regulator (Cftr), cholinergic
201 receptor muscarinic 2 (Chrm2), cannabinoid receptor 1 (Cnr1), collagens (Col1a2, 3a1, 5a2,
202 11a1), complement C3d receptor 2 (Cr2), cAMP responsive element binding protein 1 (Creb1),
203 cysteine rich transmembrane BMP regulator 1 (Crim1) crystallin zeta (Cryz), cystatin (Cst5),
204 catenin alpha 2 (Ctnna2), chemokine receptor (Cxcr4), cytochrome P450 family (Cyp26b1,
205 51a1), DAB adaptor protein 2 (Dab2), dickkopf WNT signaling pathway inhibitor 2 (Dkk2),
206 discs large MAGUK scaffold protein 2 (Dlg2), dynein light chain roadblock-type 2 (Dynlrb2),
207 EGF like repeats and discoidin domains 3 (Edil), ephrin B2 (Efnb2), ectonucleotide
208 pyrophosphatase (Ennpp2), erb-b2 receptor tyrosine kinase 4 (Erbb4), ELKS/RAB6-
209 interacting/CAST family member 2 (Erc2), estrogen related receptor gamma (Esrrg), Fas
210 associated via death domain (Fadd), fibroblast growth factor (Fgf9), four and a half LIM
211 domains 2 (Fhl2), FERM domain containing 4B (Frmd4b), fucosyltransferase 8 (Fut8),
212 polypeptide N-acetylgalactosaminyltransferase 7 (Galnt7), galanin receptor (Galr1), growth
213 associated protein 43 (Gap43), glial cell derived neurotrophic factor (Gdnf), growth hormone
214 receptor (Ghr), glutaminase (Gls), glutamate-ammonia ligase (Glul), G protein subunit gamma
215 12 (Gng12), glycerol-3-phosphate acyltransferase (Gpam), G protein-coupled receptor 63
216 (Gpr63), GPRIN family member 3 (Grin3), growth factor receptor bound protein 10 (Grb10),
217 glutamate ionotropic receptors (Gria1, Gria3, Grin2a), hyaluronan synthase 2 (Has2), histone
218 deacetylase 5 (Hdac5), hepatocyte growth factor (Hgf), 15-hydroxyprostaglandin dehydrogenase
219 (Hpgd), interleukin 15 (Il15), interleukin receptor (Il7r), inositol polyphosphate-4-phosphatase
220 type II B (Inpp4b), insulin (Ins1), integrin subunit beta 1 (Itgb1), jagged canonical Notch ligand
221 (Jag1), janus kinase 1 (Jak1), potassium voltage-gated channel (Kncab1, d2, d3, q5), kinase
222 insert domain receptor (Kdr), Kruppel like factor 4 (Klf4), leptin (Lep), luteinizing
223 hormone/choriogonadotropin receptor (Lhcgr), LIM domain 7 (Lmo7), lipoprotein lipase (Lpl),
224 latent transforming growth factor beta binding protein 1 (Ltbp1), mab-21 like 1 (Mab21l1),
225 mitotic arrest deficient 2 like 1 (Mad2l1), MAF bZIP transcription factor (Maf), membrane
226 associated guanylate kinase (Magi1,2), mal, T cell differentiation protein 2 (Mal2), mitogen-

227 activated protein kinase (Map2k6,k14), MyoD family inhibitor domain containing (Mdfic),
228 MAM domain containing glycosylphosphatidylinositol anchor 1 (Mdga1), mesoderm specific
229 transcript (Mest), myosin (Myo1b), myoferlin (Myof), NDUFA4 mitochondrial complex
230 associated (Ndufa4), Nectin cell adhesion molecule (Nectin3), neural growth regulator (Negri),
231 neuronal differentiation 6 (Neurod6), sodium/potassium transporting ATPase interacting
232 (Nkain2), natriuretic peptide receptor 3 (Npr3), neuronal pentraxin 2 (Nptx2) neuropeptide Y
233 (Npy) and receptor (Npr1r), nuclear receptors (Nr3c2-mineralcorticoid receptor; Nr5a2- liver
234 receptor 1, an essential transcriptional regulator of lipid metabolism), neuropilin 2 (Nrp2), nudix
235 hydrolase 7 (Nudt7), neurexophilin 1 (Nxph1), olfactomedin 4 (Ofm4), opioid receptor kappa 1
236 (Oprk1), PBX homeobox 1 (Pbx1), phosphodiesterase 1C (Pde1c), phospholipase A2 (Pla2g4a),
237 plexin (Plxna2, a4), peripheral myelin protein 22 (Pmp22), PPARG coactivator 1 alpha
238 (Ppargc1a), protein phosphatase 1 regulatory subunit 3B (Ppp1r3b), protein phosphatase 1
239 catalytic subunit alpha (Ppp3ca), prickle planar cell polarity protein 2 (Prickle2), prolactin
240 (Prl8a2), prolactin receptor (Prlr), polypyrimidine tract binding protein 2 (Prbp2), prostaglandin
241 E receptor (Ptger2,3,4), protein tyrosine kinase 2 (Ptk2), pentraxin (Ptx3), RALY RNA binding
242 protein like (Ralyl), Rap2b, RB binding protein 8 (Rbbp8), retinol dehydrogenase 10 (Rdh10),
243 regulator of G protein signaling (Rgs7, 18), roundabout guidance receptor 1 (Robo1), RP1
244 axonemal microtubule associated (Rp1), R-spondin 2 (Rspo2), receptor transporter protein 4
245 (Rtp4), RUNX1 partner transcriptional co-repressor 1 (Runx1t1), ryanodine receptor 2 (Ryr2),
246 sphingosine-1-phosphate receptor 1 (S1pr1), Samhd1, SATB homeobox 1 (Satb1), selenoprotein
247 P (Selnop), semaphorin 3A (Sema3a), shootin 1 (Shtn1), solute carrier (SLC1a3, 4a4, 6a11, 8a1),
248 slit guidance ligand 2 (Slit2), sphingomyelin phosphodiesterase 1 (Smpd1), sushi, nidogen and
249 EGF like domains 1 (Sned1), sortilin related VPS10 domain containing receptor 3 (Sorcs3),
250 SPHK1 interactor, AKAP domain containing (Sphkap), SPARC-osteonectin (Spock3), sprouty
251 related EVH1 domain, Steap1, containing 2 (Spred), serine/threonine kinase 3 (Stk3), tachykinin
252 precursor 1 (Tac1), threonyl-tRNA synthetase 1 (Tars1), Tcb1d9, TBL1X receptor 1 (Tbl1xr1),
253 tissue factor pathway inhibitor 2 (Tfpi2), thyroglobulin (Tg), thyroid hormone beta (Thrb), toll
254 like receptor 4 (Tlr4), transmembrane (Tm4sf1, Tmem72, Tmem74), TNF (Tnfsf11) and TNF
255 receptor (Tnfsf11b), tensin 3 (Tns3), translocation associated membrane protein 1 (Tram1),
256 thyroid releasing hormone receptor (Trhr), tripartite motif containing 24 (Trim24),
257 transcriptional repressor GATA binding 1 (Trps1), UDP glycosyltransferase 8 (Ugt8), vascular
258 endothelial growth factor C (Vegfc), Wnt2, Wnt2b, Xkr4, zinc finger (Zbtb18, Zfhx3, Zfpm2,
259 Zmat3).

260

261 ***Analysis of overlap of protein coding genes closest to ChIP-seq peaks with genes exhibiting***
262 ***circadian rhythms of expression in mammary and liver BMAL1 target genes.*** A secondary
263 approach to verify BMAL1 targets identified with ChIP-seq, was to query for overlap of targets
264 with genes that exhibited circadian rhythms of expression in mammary tissue or identified as
265 BMAL1 targets in hepatic tissue. The set of genes (Supplemental Tables S2 and S3) used as

266 potential BMAL1 targets was relaxed for this analysis, and although genes were common among
267 two to four ChIP samples the peaks did not necessarily overlap. Genes identified as potential
268 targets in UNDIFF and DIFF samples overlapped with 102 genes that exhibited circadian
269 rhythms of expression in virgin mouse glands[13] and 189 in lactating breast of women[14].
270 Functional annotation analysis of overlap between mammary circadian rhythm transcriptomes
271 and potential BMAL1 targets categorized thirteen genes in GO:0006974~*cellular response to*
272 *DNA damage stimulus* (Supplemental Table S15 and Table 2). Nine genes were clustered in
273 GO:0006629~*lipid metabolic process* including, *Fdft1*, *Gpam*, a thromboxane synthase (*Tbxas1*),
274 and several lipases (*Mgll*, *Plcg2*, *Plcl2*, *Pla2g4a*). Other genes overlapping between mammary
275 transcriptomes and potential BMAL1 targets were *Pfkp*, which catalyzes the first step of
276 glycolysis, *Prdx6*, which encodes an antioxidant protein, several homeobox transcription factors
277 (*Sox13*, *Sox 17*, *Fox II*), the mineralcortin receptor (*Nr3c2*), and the transcription factor
278 thyrotroph embryonic factor (*Tef*).

279 Analysis of overlap of BMAL1 targets in HC11 cells with high confidence BMAL1
280 targets of protein coding genes in hepatic tissue[19] found 244 in common between liver and
281 mammary epithelial cells. Categories genes enriched included *lipid metabolic process transport*
282 (e.g. transporters for citrate-*Scl13a2*, amino acids-*Slc25a13*, lactate, pyruvate- *Slc16a7*, glucose-
283 *Slc2a2*, and several ABC transporters), *positive regulation of transcription from RNA*
284 *polymerase II promoter*, and 7 (3%) in *circadian rhythm* (Supplemental Table S16 and Table 2).
285 ***Impact of CRISPR-CAS knockout of BMAL1 on HC11 cell growth, differentiation and***
286 ***metabolic activity.*** To validate targets and gain an understanding of the functional role that
287 BMAL1 plays in regulation of mammary epithelial cell growth and differentiation, a monoclonal

288 line with the BMAL1 gene knocked out (i.e. deleted; BMAL1-KO) using CRISPR-CAS9
289 technology was created. PCR analysis prior to monoclonal selection demonstrated the donor

Table 2. Representative categories enriched with potential BMAL1 target genes identified using ChIP-seq that overlapped with genes that showed circadian rhythms of expression in mammary glands and high confidence BMAL1 targets identified in hepatic tissue

| Term | Count | % | P-value | Genes |
|---|-------|------|----------|---|
| Overlap with genes that showed circadian rhythm of expression in mammary glands | | | | |
| Endoplasmic reticulum | 27 | 10.9 | 3.43E-05 | Ankle2, Hsd11b2, Dnase1l3, Syvn1, Rnf103, Scara3, Tmx1, Lrrc8d, Map3k5, Rdh10, Tbxas1, Slc37a1, Ktn1, Creb3l2, Ext1, Anp32a, Sulf2, Fmo1, Ckap4, Fdft1, B3gat1, Ankrd13c, Itpr1, Fgfr3, Nr3c2, Slc35b1, Itpr3 |
| GO:0016567~protein ubiquitination | 10 | 4.0 | 0.03 | Wwp1, Ppil2, Fancl, Trim24, Rnf103, Syvn1, Nsmce2, Tulp4, Kbtbd2, Klhl23 |
| GO:0006974~cellular response to DNA damage stimulus | 11 | 4.4 | 0.03 | Parp1, Fancl, Apc, Ubr5, Prkdc, Nsmce2, Ascc3, Mapk14, Npas2, Erc4c, Clock |
| GO:0006629~lipid metabolic process | 9 | 3.6 | 0.2 | Plcl2, Gpam, Tbxas1, Dagla, Fdft1, Prdx6, Plcg2, Mgll, Pla2g4a |
| Overlap with high confidence BMAL1 targets in hepatic tissue | | | | |
| IPR000536:Nuclear hormone receptor, ligand-binding, core | 9 | 3.6 | 8.2E-08 | Ppara, Nr5a2, Esrrg, Rarb, Nr3c2, Nr2f2, Nr1d1, Nr1i2, Rora, |
| GO:0006629~lipid metabolic process | 17 | 6.9 | 2.1E-04 | Isyna1, Hsd17b2, Gpam, Fdft1, Pten, Prdx6, Vldlr, Aspg, Mgll, Ptxd2, Ppara, Cyp7b1, Plcg2, Plin5, Mogat1, Pcx, Insig2 |
| GO:0055085~transmembrane transport | 15 | 6.1 | 1.9E-04 | Slc17a9, Slc22a4, Slc25a13, Slc2a2, Slc22a15, Trpm7, Itpr2, Slc13a2, Abcg2, Itpr1, Slc16a7, Abcb4, Abca8a, Mfsd1, Slc25a44 |
| GO:0045944~positive regulation of transcription from RNA polymerase II promoter | 29 | 11.8 | 4.6E-05 | Prox1, Tlr2, Nr5a2, Maf, Chd7, Smad2, Tnks, Pcbp1, Klf13, Tet2, Parp1, Tef, Cnot7, Pou2f1, Nr1i2, Crtc1, Rarb, Zfp292, Smarca2, Tfdp1, Rora, Ccnh, Ppara, Arid2, Auts2, Esrrg, Med13, Prrx1, Mtf2 |

290 cassette was integrated into target sites using both available guide RNAs (gRNA1 and gRNA2;
291 Supplementary Figure S3). Western blot analysis found complete loss of BMAL1 protein
292 expression in several monoclonal lines and supported homozygous knockout of BMAL1 gene
293 was achieved with CRISPR-CAS 9 (Figure 3a). Following Sanger sequencing to confirm
294 genomic integration of green fluorescent protein from the donor cassette (Supplementary Table
295 S17), a monoclonal BMAL1-KO line created using gRNA1 was selected to use for all

296 subsequent studies. Temporal analysis of circadian *Per2* expression indicated 24 hr rhythms of
297 gene expression in wild type HC11 ($R^2= 0.85$; p -value= 0.00008; amplitude= 1.58) cells, and an
298 attenuation of rhythms in the BMAL1-KO ($R^2= 0.47$; p -value= 0.04; amplitude= 0.70) line
299 (Figure 3b). Consistent with our previous results[5, 18] expression of BMAL1 protein increased
300 in lactogen DIFF versus UNDIFF HC11 cultures (Figure 3c).

301 **Supplemental Figure S3.** (a) PCR Analysis of monoclonal donor cassette integration. The first
302 10 lanes contain DNA from monoclonal colonies post clonal selection. The first character of
303 each name refers to the gRNA used (i.e. 1A is HC11 that has undergone integration using gRNA
304 1). NTC denotes a no-template negative control. These results indicate proper integration of the
305 donor cassette into the target site of cell colonies 1B, 1C, 2A, 2B, 2C, and 2D.

306 **Figure 3.** (a)Western blot analysis of BMAL1 protein abundance in HC11 and monoclonal
307 colonies (1A, 1B, 1C, 2A, 2B, 2C, 2D) established from CRISPR-CAS transfected with guide
308 RNA (gRNA) targeting BMAL1 gene post monoclonal selection. BMAL1 is absent in colonies
309 1C and 2D and decreased in the remaining colonies compared to WT HC11. Monoclonal 1C
310 culture was used in all subsequent experiments, and referred to as BMAL1-KO. Data are
311 representative of two western blots. (b) Temporal analysis of *Per2* expression in WT HC11
312 (solid line) and BMAL1-KO (dashed line) cultures. For this experiment cells were grown to
313 confluence in growth media. Media was changed to lactogen media for 2 hr to synchronize
314 clocks. At completion of 2 hr lactogen treatment (time 0 hr), cells were rinsed with PBS and
315 cultured in growth media for remainder of the experiment. Cells were collected for isolation of
316 total RNA every 4 hr over a 48 hr period beginning at 0 hr. *Per2* was measured with q-PCR, and
317 levels were expressed relative to mean levels across all time points of HC11 culture. Cosinor
318 analysis found mesor (-0.12 and -0.68), amplitude (1.58 and 0.70), acrophase (0.78 and -0.56),
319 R^2 (0.85 and 0.47) and p -value (8.05 E-5 and 0.04) of fit to a 24 hr rhythm were calculated,
320 respectively, for HC11 and BMAL1-KO lines. Data represent n=3 wells/line and 2 experimental
321 replicates. (c) BMAL1 protein abundance in UNDIFF and DIFF cultures measured using ELISA.
322 Data are expressed as mean μ g of BMAL1/mg protein \pm standard deviation of three samples per
323 treatment; * indicates difference at $p<0.05$. Data represent n=3 protein isolates/line/state of
324 differentiation.

325 Eight-day growth curve analysis showed that although doubling time between wild-type
326 HC11 and BMAL1-KO lines was not different ($p>0.05$), with HC11 at 21.9 ± 3.8 hr and
327 BMAL1-KO at 26.9 ± 3.8 hr, the BMAL1-KO line reached stationary phase at a significantly
328 lower cell density than wild-type HC11 cells ($p<0.05$; Figure 4a). The MTT assay found a
329 similar pattern as the eight-day growth curve (Figure 4b). Analysis of images captured on days 2

330 and 6 of culture (Figure 4d) found less cells and lower ($p<0.05$) intensity of MTT staining per
331 unit area of cells in BMAL1-KO cultures (Figure 4c), indicating that BMAL1-KO cultures had
332 less cells and lower metabolic activity per cell than wild-type HC11 cultures. FACS analysis
333 found no difference between HC11 and BMAL1-KO in the proportion of cells in G1/G0 and
334 S/G2/M phase of the cell cycle across the eight days (Figure 4e). FACS screening for cells with
335 less than 2N, an indicator of dead or dying cells, found a higher percent in BMAL1-KO cultures
336 on all eight days ($p<0.05$; Figure 4f). Despite no difference in the percent of cells in S/G2/M
337 phases, the expression level of *Ccnd1*, which regulates the transition from G1 to S phase of the
338 cell cycle, was greater ($p<0.05$) in BMAL1-KO line (Figure 4g).

339 **Figure 4.** Effect of BMAL1 CRISPR-CAS knockout (BMAL1-KO) on growth and metabolic
340 activity in culture. (a) Eight day growth curve analysis was performed by plating 100,000 cells/
341 well on day 0 in 6 well dish of wild type HC11(black line) and BMAL1-KO (gray line), two
342 wells/treatment were collected and counted every two days; values are mean \pm standard
343 deviation across five experiments. Two way ANOVA found that line and day significantly
344 affected ($p<0.05$) number of cells. Data represent five experimental replicates, with $n=2$
345 wells/line per experiment. (b) MTT assay was performed by plating HC11 (black bars) and
346 BMAL1-KO (gray bars) cells at 10,000 cells/well in a 96-well plate; on days 2, 4, 6 and 8 of
347 culture, MTT assay was performed. ANOVA found line and day significantly affected NADH
348 levels; values are mean \pm standard deviation; * indicates difference between lines at $p<0.05$
349 across 3 replicate experiments. Data represent three replicate experiments collected from $n=3$
350 wells/line/day. (c) The intensity of MTT staining per cell across three images on each day in
351 HC11 (black) and BMAL1-KO (gray) cultures was quantified. Values are mean intensity per cell
352 \pm standard deviation. A significant difference at $p<0.05$ is indicated by *. (d) Images of cells
353 were captured following staining with the MTT assay on day 2 and 6 of culture. (e) Cells were
354 collected from 100 mm dishes (plating density was 100,000 cells/ml) for fluorescence activated
355 cell sorting (FACS) to determine percent of cells in G1/G0 and S/G2/M phases following
356 labeling with propidium iodide across 8 days of culture. Values are mean across 5 experiments,
357 with ANOVA analysis finding that day had an effect ($p<0.05$) on proportion of cells in phases,
358 but there was no difference between HC11 (black) and BMAL1-KO (gray). (f) FACS analysis
359 for dead or dying cells (cells or events with $<2N$) in HC11 (black) and BMAL1-KO (gray).
360 Values are percent of total events \pm standard error; * indicates difference at $p<0.05$. (g) q-PCR
361 analysis of *Ccnd1* and *Sod3* expression in undifferentiated (UNDIFF) cultures of HC11 (black)
362 and BMAL1-KO (gray) cells. Values are mean across triplicate samples and two experimental
363 replicates, normalized to express fold-change relative to mean of HC11 \pm standard deviation
364 using delta-delta cycle threshold method; Student t-test analysis * indicates difference between
365 lines at $p<0.05$. (h) Reactive oxygen species (ROS) assay of HC11 and BMAL1 cells on day 3
366 and 4 of culture. Two-way ANOVA found day and line affected ($p<0.05$) ROS levels; *

367 indicates difference between lines at $p < 0.05$ across 3 replicate experiments n=3 wells/line/day;
368 values are mean of arbitrary units (AU) \pm standard deviation.

369

370 Others reported that transgenic mice with BMAL1 gene knocked out (*Bmal1*^{-/-}) had
371 reduced lifespans and displayed symptoms of premature aging associated with increased levels
372 of reactive oxygen species in some tissues[20]. To determine if this was the potential cause of
373 cell loss in BMAL1-KO line, reactive oxygen species (ROS) were measured and found to be
374 significantly higher in BMAL1-KO cultures on days measured (Figure 4h). Q-PCR analysis of
375 the antioxidant *Sod3*, which was identified as a potential target of BMAL1 in HC11 cells,
376 revealed that mRNA levels were significantly lower in BMAL1-KO versus wild-type HC11
377 cultures (Figure 4g).

378 In the DIFF2 sample the serotonin transporter-SERT (*Slc6a4*) and tryptophan
379 hydroxylase 1 (*Tph1*), which encodes the protein that catalyzes the first and rate-limiting step in
380 the biosynthesis of serotonin, were identified as potential targets. Lactogen induced
381 differentiation of HC11 cells significantly increased mRNA levels of *Tph1* (Figure 5a) and *Sert*
382 (Figure 5b), whereas levels were significantly lower in the BMAL1-KO line. Q-PCR analysis
383 using primers that targeted two sites in the *Sert/Slc6a4* promoter region that contained E-box
384 sequences beginning at -42 and -1282 nucleotide bases upstream of the transcriptional start site,
385 found levels 3.5-fold and 2-fold, respectively, higher in UNDIFF BMAL1 ChIP samples than
386 mock-IP samples (Figure 5c). Although only one DIFF sample had a peak in the promoter
387 region of the *Sert/Slc6a4* gene (Supplemental Figure S4f).

388 **Figure 5.** Quantitative-PCR (q-PCR) analysis of (a) *Tph1* and (b) *Slc6a4* (*Sert*) in
389 undifferentiated (UNDIFF) and lactogen differentiated (DIFF) HC11 (black) and BMAL1-KO
390 (gray) cultures. Values are mean across triplicate samples and two experimental replicates,
391 normalized to express fold-change relative to mean of HC11 \pm standard deviation using delta-

392 delta cycle threshold method; ANOVA and post-hoc Tukey test analysis indicated with differing
393 letter reflecting difference at $p<0.05$. (c) qPCR analysis of *Slc6a4* (*Sert*) promoter region using
394 primers that targeted two sites that contained E-box sequences beginning at -42 and -1282
395 nucleotide bases upstream of the transcriptional start site in undifferentiated HC11 cultures;
396 values are mean across four samples, normalized to express fold-change relative to mean of
397 mock \pm standard deviation. A 2-fold difference was considered a positive ChIP.

398 **Supplemental Figure S4.** Figures represent reads/samples in wig format where Input reads are
399 subtracted from IP reads. Reads per sample of peaks closest to: *Ppara* zoomed out (a) and in (b);
400 *Prlr* (c) and (d); *Fasn* (e); *Slc6a4* (f); *Per1* (g); and *Csn2* (h) transcriptional start sites.

401 *Ppara*, which regulates lipid metabolism and glucose homeostasis, was also identified as
402 a potential target in both DIFF samples (Supplemental Figure S4a and S4b) as well as in the
403 liver[19]. Q-PCR analysis of *Ppara* expression levels found mRNA depressed in UNDIFF and
404 DIFF BMAL1-KO cultures relative to wild-type HC11 (Figure 6a). Fatty acid synthase (*Fasn*)
405 was identified as a potential target of BMAL1 in both DIFF samples (Supplemental Figure S4e).
406 However, q-PCR analysis across experimental replicates showed variable results (Supplemental
407 Figure S5a-c). Moreover, temporal of *Fasn* mRNA expression across a 48 hr period indicated
408 lack of a fit ($p>0.05$) to a 24 hr rhythm (Supplemental Figure S5c). Therefore, it was concluded
409 that *Fasn* mRNA levels were not different between BMAL1-KO and HC11 lines.

410 **Supplemental Figure S5.** Quantitative-PCR (q-PCR) analysis of *Fasn* of HC11 (black) and
411 BMAL1-KO (gray) cultures in replicate experiments of undifferentiated (UNDIFF) and lactogen
412 differentiated (DIFF) cultures. Values are mean technical replicates within experiment,
413 normalized to express fold-change relative to mean of HC11 \pm standard deviation using delta-
414 delta cycle threshold method. Temporal analysis of *Fasn* expression in WT HC11 (solid line)
415 and BMAL1-KO (dashed line) cultures. For this experiment cells were grown to confluence in
416 growth media. Media was changed to lactogen media for 2 hr to synchronize clocks. At
417 completion of 2 hr lactogen treatment (time 0 hr), cells were rinsed with PBS and cultured in
418 growth media for remainder of the experiment. Cells were collected for isolation of total RNA
419 every 4 hr over a 48 hr period beginning at 0 hr. *Fasn* was measured with q-PCR, and levels
420 were expressed relative to mean levels across all time points of HC11 culture. Cosinor analysis
421 found mesor (0.01 and 0.97), amplitude (0.21 and 0.12), acrophase (-9.14 and -4.44), R^2 (0.26
422 and 0.19) and p -value (0.22 and 0.33) of fit to a 24 hr rhythm were calculated, respectively, for
423 HC11 and BMAL1-KO lines.

424

425 **Figure 6.** Quantitative-PCR (q-PCR) analysis of (a) *Ppara* and (b) *Csn2* in undifferentiated
426 (UNDIFF) and lactogen differentiated (DIFF) HC11 and BMAL1-KO cultures. Values are mean
427 across triplicate samples and two replicate experiments, normalized to express fold-change
428 relative to mean of HC11 \pm standard deviation using delta-delta cycle threshold method. Note
429 the y-axis in *Ppara* is fold change, whereas y-axis for *Csn2* is log base 2 of fold change due to
430 large induction. ANOVA and post-hoc Tukey test analysis findings is indicated by differing
431 letter reflecting difference at $p < 0.05$. (c) ELISA quantification of CSN2 protein in UNDIFF and
432 DIFF HC11 (black) and BMAL1-KO (gray) cultures. Values are mean concentration \pm standard
433 deviation across triplicate samples. ANOVA and post-hoc Tukey test analysis findings is
434 indicated by differing letter reflecting difference at $p < 0.05$. (d) q-PCR analysis of *Prlr* in
435 UNDIFF and lactogen DIFF HC11 (black) and BMAL1-KO (gray) cultures. Values are mean
436 across triplicate samples, normalized to express fold-change relative to mean of HC11 \pm standard
437 deviation using delta-delta cycle threshold method. Note the y-axis is fold change. ANOVA and
438 post-hoc Tukey test analysis findings is indicated by differing letter reflecting difference at
439 $p < 0.05$. (e) Images of two and a half dimensional drip gel cultures of HC11 and BMAL-KO cells
440 taken with phase-contrast microscopy after 7 days of incubation in lactogen media. Cells were
441 plated at 13,000 cells/well.

442

443 Although *Csn2*, which encodes the milk protein beta-casein, was only identified as a
444 potential target in one of the differentiated samples (DIFF2), levels of mRNA (Figure 6b) and
445 protein (Figure 6c) were lower in BMAL1-KO versus wild-type HC11 lines. Prolactin regulates
446 *Csn2* expression and the prolactin receptor (*Prlr*; Supplemental Figure S4c and S4d) was
447 identified as a BMAL1 target. *Prlr* mRNA expression was reduced in UNDIFF and DIFF
448 BMAL1-KO cultures (Figure 6d). Lower *Prlr* levels would affect multiple pathways that
449 stimulate mammary epithelial cell differentiation. The ability of mammary epithelial cells to
450 differentiate can be evaluated by acini formation in Matrigel, a laminin rich extracellular matrix
451 extract.[21] After seven days in culture, wild-type HC11 cells formed many relatively large
452 acini, whereas BMAL1-KO cultures primarily failed to do so, and acini that were formed were
453 much smaller in size (Figure 6e).

454

455

456

DISCUSSION

457 Genes identified in undifferentiated and lactogen differentiated mammary epithelial cells as
458 potential transcriptional targets of BMAL1 support the hypothesis that the circadian clock in the
459 mammary gland regulates mammary development and lactation, and that transcriptional targets
460 of BMAL1 change as mammary epithelial cells differentiate. The greater number of
461 transcriptional targets in differentiated HC11 cultures were likely due, in part, to the effects of
462 lactogenic hormones on chromatin access. Higher doses of glucocorticoid treatment are
463 associated with pioneering activities of glucocorticoid receptors. Binding of activated
464 glucocorticoid receptors to chromatin increases the accessibility of regions of the genome
465 previously inaccessible to other transcription factors.[22, 23]. Prolactin (*Prl8a2*) and the
466 prolactin receptor (*Prlr*) were identified as BMAL1 targets. Prolactin regulates *Bmall* expression
467 in mammary epithelial cells [5], and mammary epithelial cells synthesize and secrete prolactin
468 [24]. Thus, in differentiated mammary epithelial cells BMAL1 may play a role in the iterative
469 induction of its own activity through positive loops with prolactin signaling. Upon prolactin
470 binding to its receptor JAK2 is activated. *Jak2* was also identified as a BMAL1 target.
471 Activated JAK2 phosphorylates and activates STAT5 transcription factors. Activated STAT5
472 transcription factors were associated with pioneer-like effects on chromatin in mammary
473 epithelial cells [25]. Thus, the higher number of BMAL1 targets in the lactogen differentiated
474 cultures may have been due to dexamethasone and prolactin treatments increasing the
475 accessibility of BMAL1 to chromosomal regions. Moreover, the positive loop between BMAL1
476 and prolactin signaling molecules may potentially explain the changes in stoichiometric
477 relationships between positive and negative elements of the mammary epithelial clock

478 transcription-translation feedback loop observed following lactogen induced cellular
479 differentiation [5].

480 The prediction of CREB as an upstream regulator of BMAL1 targets is consistent with
481 CREB's role as a coactivator of BMAL1:CLOCK transcription factor activity [26, 27]. Genes
482 identified as CREB targets encompassed cell adhesion molecules (cadherins, catenin and nectin
483 genes), leptin, lipoprotein lipase, and estrogen receptor gamma. The prediction of the glutamate-
484 regulated ion channel GRIN3A as the most significant upstream regulator of BMAL1 target
485 genes, suggest that, similar to the role that glutamate places in regulation of the master clock in
486 the SCN [28], it potentially entrains circadian rhythms in mammary epithelial cells. Moreover,
487 the identification of chorionic gonadotropin complex as an upstream regulator of BMAL1 target
488 genes may reflect a potential role of the mammary epithelial clock in integration and
489 coordination of the timing of endocrine-paracrine signal-receptivity-response. Among the
490 targets downstream of this complex were receptors for mineralcorticoid (*Nr3c2*), prolactin (*Prlr*),
491 prostaglandin E (*Ptger2*), natriuretic peptide (*Npr3*), luteinizing hormone/choriogonadotropin
492 (*Lhcgr*), bone morphogenetic protein (*Bmpr1b*). In addition, there were receptors for Wnt
493 ligands (*Fzd1*), ephrins (*Epha3* and *Epha7*), an integrin (*Itgb1*), and the orphan nuclear receptor
494 *Nr5a2*, which acts as a metabolic sensor that regulates expression of genes involved in bile acid
495 synthesis, cholesterol homeostasis and triglyceride synthesis.

496 Among the BMAL1 targets identified were multiple components of the Wnt signaling
497 pathway (*Wnt2*, *Wnt2b*, *Fzd1*, *Rspo2*, *Ctnna2*) and *Cdk14*, which acts as a cell-cycle regulator of
498 Wnt signaling pathway. The Wnt signaling pathway influences mammary stem cells to elicit
499 fate specification and patterning during embryonic and postnatal development of the gland[29].
500 Regulation of the Wnt/β-catenin pathway by the circadian clock has been demonstrated in

501 epidermal stem cells [30]. Alterations in expression level of genes in the Wnt pathway may
502 potentially be the cause of compromised mammary epithelial stem cell function observed in
503 *Clock*-Δ19 mice[13], as well as the premature aging evident in *Bmall*-/- mice[31]. The nuclear
504 hormone receptors for glucocorticoids, retinoids, and estrogens also regulate adult stem cell fate
505 [31]. Retinoic acid receptor beta (*Rarb*), the orphan receptor estrogen-related receptor gamma
506 (*Esrrg*), which interferes estrogen receptor signaling, and the mineralcorticoid receptor (*Nr3c2*),
507 which binds glucocorticoids, were found among the potential targets of BMAL1 in mammary
508 epithelial cells. Additional evidence that the clock in mammary epithelial cells may regulate cell
509 fate and developmental patterning was the network generated by IPA software that indicated
510 BMAL1 targets affected branching of cells, development of organs, and body size, while
511 inhibiting cell death. Moreover, numerous BMAL1 targets were involved in stem cell
512 maintenance to include *Sox1* and *Sox6* [32] and *Pard3* and *Pard3b* genes. *Pard3* is necessary for
513 mammary gland morphogenesis, and *Pard3b* is expressed by multipotent stem cells in the
514 terminal end buds of murine mammary glands, with studies finding ablation of *Pard3b* resulted
515 in stem cell loss [32].

516 Also among the BMAL1 targets were a multitude of ion transporters, solute carriers,
517 glutamate transporters and ATP-binding cassette transporters. Synthesis and secretion of milk is
518 dependent on membrane transport systems that move ions and substrates into and out of
519 epithelial cells [33, 34]. Movement of ions by ion transporters creates potential differences that
520 enable electrical signaling which regulates cell number, shape, differentiation, and
521 morphogenesis [35]. Glutamine is the primary nitrogen donor for proliferating cells, and
522 alterations in intracellular glutamine abundance was associated with quiescent and proliferative
523 states of mammary epithelial cells [36]. Glutamine also contributes carbons to biosynthetic

524 reactions, and thus mammary clock regulation of glutamate transport may be a means by which
525 the timing of proliferation and metabolic activities of epithelial cells are coordinated. Of the ten
526 ATP binding cassette genes identified as BMAL1 targets seven were the ABCA subfamily type,
527 which function to mediate efflux of cholesterol (*Abca1*) and other lipids from cells. Others
528 included *Abcc12*, which mediates toxin efflux, the xenobiotic transporter *Abcg2*, and *Abcb5*,
529 which may also function in the efflux of drugs and toxins. Thus, enrichment of pathways and
530 categories related to ion channels, synapse and substrate transports point to the potential role of
531 the mammary clock in affecting the program of mammary development as well as regulating
532 substrate availability and detoxification during lactation.

533 Functional studies with the BMAL1-KO line found that deletion of *Bmal1* did not affect
534 proliferation rate of cells, but rather resulted in greater rates of cell death and lower metabolic
535 activity. Although, *Ccnd1* was identified as a potential BMAL1 target, deletion of *Bmal1* gene
536 resulted in significantly higher expression of *Ccnd1* in BMAL1-KO cultures. Similarly, when
537 abundance of CLOCK protein was decreased in HC11 cells with shRNA, *Ccnd1* expression was
538 higher and proliferation rate increased[18]. In our previous study, lower CLOCK abundance
539 appeared to result in the loss of gating of entry and progression through the cell cycle. Elevated
540 *Ccnd1* likely reflected this phenomena in culture, and thus loss of gating may also explain
541 elevated *Ccnd1* levels in BMAL1-KO cells. Gating the time cells enter the cell cycle by clocks
542 enables the sequestering of processes incompatible with DNA synthesis[37]. Loss of gating
543 time, coupled with increased levels of reactive oxygen species,
544 related to lower *Sod3* expression, in BMAL1-KO cells may have resulted in genotoxic stress, and
545 cell death. There were 31 BMAL1 targets that encoded proteins involved in response to DNA
546 damage, to include *Cdkn2aip*, *Nsmce2*, *Rad23b*, *Hus1*, *Ubr5*, *Ube2e2*, *Ube2w*. Thus, death of

547 BMAL1-KO cells was also potentially due to decreased ability to repair DNA damaged by
548 reactive oxygen species. Moreover, *Ubr5*, *Ube2e2*, *Ube2w* are involved in the ubiquitination
549 pathway. The ubiquitination pathway targets proteins for degradation and plays a central role in
550 maintaining proteostasis, the cellular balance of protein synthesis and degradation. The aging
551 process is related to changes in proteostatic equilibrium and build-up of misfolded and damaged
552 protein aggregates[38, 39], and thus the observation that Bmal1 knockout mice (*Bmal1* *-/-*)
553 exhibited advanced aging[20], may be due to alterations in these genes and the ubiquitination
554 pathway.

555 Involvement of BMAL1 targets in proteostasis supports that the mammary epithelial
556 clock regulates cellular-tissue homeostasis. During lactation, the serotonergic system plays a
557 central role in regulating mammary epithelial cell homeostasis [40]. Multiple components of the
558 serotonergic system were identified as potential BMAL1 targets in several of the samples. TPH1
559 and SERT/SLC6A4 are central to serotonergic regulation of mammary epithelial homeostasis
560 through regulation of synthesis and degradation of serotonin, respectively. Our previous analysis
561 found multiple E-box sequences in the promoter region *Sert/Slc6A4* and *Tph1* genes, and that
562 SERT exhibited circadian rhythms of expression in HC11 cells and lactating sheep
563 mammary[41]. ChIP-qPCR analysis of regions encompassing E-box sequences in the promoter
564 regions of SERT confirmed BMAL1 binding to these sites in HC11 cells. Levels of *Sert* and
565 *Tph1* were also significantly depressed in BMAL1-KO cultures relative to wild-type HC11. The
566 circadian system functions in part to maintain metabolic homeostasis[42], and thus a role for the
567 mammary clock in regulating factors that control epithelial homeostasis during lactation is
568 consistent with this function.

569 *Lipid metabolic process* was enriched with BMAL1 target genes, and these overlapped
570 with genes that showed circadian rhythms of expression in mammary and those that were
571 confirmed targets of BMAL1 in hepatic tissue. Notable among them were *Fdft1*, *Gpam*, *Vldlr*,
572 *Plin5* and *Mgll*, all of which increase significantly upon secretory activation of the mammary
573 gland[43, 44], a process marked by the onset of milk fat synthesis and secretion. FDFT1
574 (farnesyl-diphosphate farnesyltransferase 1) regulates cholesterol synthesis, GPAM catalyzes the
575 synthesis of glycerolipids, VLDLR and MGLL function in the uptake and hydrolysis of
576 triglycerides, and PLIN5 mediates lipid droplet formation. Together supporting that the
577 mammary epithelial clock plays a central role in the regulation of milk fat synthesis during
578 lactation.

579 Also central to lipid metabolism is PPARA (peroxisome proliferator-activated receptor-
580 alpha). As a nuclear receptor it senses hormonal and nutrient status of the cell and functions to
581 stimulate uptake, utilization, and catabolism of fatty acids[45]. Q-PCR analysis of *Ppara*
582 expression showed that levels were significantly depressed in UNDIFF and DIFF cultures of
583 BMAL1-KO cells versus wild-type HC11, and failed to increase following four days of lactogen
584 treatment. These findings are consistent with the knowledge that PPARA is a well characterized
585 target of the BMAL1:CLOCK transcription factor and believed to be central to coordinating
586 cellular energy metabolism with molecular clocks[45]. The interaction of the mammary clock
587 and PPARA likely explain changes observed in milk composition that occurred with night
588 restricted feeding in dairy cattle[46]. The transport of nutrients also appears to be under the
589 control of the mammary epithelial clock as multiple transporters showed overlap with high
590 confidence BMAL1 targets in hepatic tissue to include citrate, amino acid, lactate, pyruvate, and

591 glucose transporters, and thus potentially also affected circadian rhythms of milk component
592 synthesis.

593 Fatty-acid synthase (FASN) is the enzyme that catalyzes the first committed step in fatty-
594 acid biosynthesis, and products of FASN mediated synthesis serve as PPARA ligands[47, 48].
595 Despite FASN being identified as a BMAL1 target in HC11 cells, there was lack of a significant
596 effect of deletion of BMAL1 on *Fasn* expression. This finding maybe due to the integrated and
597 reciprocal regulation of FASN products and PPARA activation[47-50].

598 BMAL1 expression is significantly increased during the transition from pregnancy to
599 lactation in mouse mammary glands, and this increase is modelled in lactogen treatment of HC11
600 cells (results and [5]). The increase in BMAL1 is likely a direct response to increased prolactin
601 and prolactin induced signaling in lactogen treated cells and at the onset of lactation, as discussed
602 above. The prolactin receptor (*Prlr*) was identified as a BMAL1 transcriptional target in HC11
603 cells, and levels of mRNA were significantly depressed in undifferentiated and lactogen
604 differentiated BMAL1-KO cultures. Lower levels of *Prlr* would affect all pathways regulated by
605 prolactin, which is a key hormone in induction of mammary epithelial cell growth,
606 differentiation and milk component synthesis[51]. The lower expression of the milk protein
607 beta-casein (*Csn2*) in DIFF BMAL1-KO cultures, and the reduced ability of this line to form
608 acini in culture were likely due, at least in part, to the lower level of prolactin receptors.

609 *Cell adhesion, cell junction* and *proteolysis* were categories highly enriched with BMAL1
610 targets identified in HC11 cells. Cell-cell and cell-extracellular matrix (ECM) interactions play a
611 central role in mammary morphogenesis and regulation of milk synthesis[41]. BMAL1 targets
612 within cell adhesion included fourteen cadherin molecules and three atypical cadherins.
613 Cadherins make-up the extracellular and transmembrane component of adherens junctions and

614 function as cell-cell adhesion receptors that mediate interactions between adjacent cells. The
615 cytoplasmic component of adherens junctions is a multiprotein complex that links adherens
616 junctions with the actin cytoskeleton[52]. The actin cytoskeleton is hypothesized to function to
617 relay SCN-driven timing cues to gene expression in peripheral tissues[53]. Thus, it is not
618 surprising that the mammary clock would control cellular components that connect to factors that
619 transmit temporal information within cells. The dramatic decreased ability of BMAL1-KO cells
620 to form acini in culture likely reflect loss of activity in cell-cell and cell-ECM adhesion
621 molecules that are critical to the morphogenesis and differentiation of mammary epithelial cells.
622 Cell-cell and cell-ECM junctional complexes sense environmental changes and function to
623 maintain mammary epithelial homeostasis[54]. Changes in mechanical tension affect circadian
624 clocks in mammary glands of virgin mice[13]. Adhesion molecules and proteolytic enzymes can
625 affect the environment of the cells, and it has been hypothesized they mediate circadian timing in
626 the central nervous as they can sense rapid signaling events and transmit-transfer signals into
627 broader changes in cell activity with the daily changes[55].

628 There are several limitations to our studies. When the frequency of peak location of
629 BMAL1 targets found in our study were compared with findings of others, the rate of intergenic
630 sites was higher in our data set and the frequency of peaks found in promoter regions was lower
631 [56]. The frequency of regions of peaks identified were consistent across the four samples
632 analyzed in our study. Therefore, the difference may be tissue or cell type specific, as our studies
633 were conducted using a mammary epithelial cell line, whereas the other group conducted studies
634 using liver tissue from mice. Additionally, to cast a wider net for identification and functional
635 annotation of BMAL1 target genes, the stringency for peak calling was relaxed from the default
636 settings of HOMER, and in doing so the number of false-positives likely increased. To increase

637 the confidence in BMAL1-targets, genes with overlapping peaks were highlighted in the
638 manuscript. When genes identified in our study were compared with datasets of genes that
639 showed circadian rhythms of gene expression in mammary tissue or identified as BMAL1 targets
640 in hepatic tissue, overlapping between datasets was only realized when criteria were further
641 relaxed to common genes identified, but peaks did not necessarily overlap between samples.
642 Similarly, only when this more relaxed selection criterion was used, were BMAL1 (ARNTL) and
643 CLOCK identified as significant upstream regulators predicted by IPA.

644 Another limitation to the studies described here, is that circadian rhythms of gene
645 expression and BMAL1 binding activity were not measured. Although robust circadian rhythms
646 of core clock genes are evident in UNDIFF HC11 cells, constant exposure to lactogenic
647 hormones, which is required to differentiate cells, results in loss of circadian rhythms of
648 expression of multiple core clock genes [4, 5]. Loss of circadian rhythms of core clock genes'
649 expression also occurred in mice in early lactation and resulted in relatively constant levels of
650 BMAL1:CLOCK transcription factor. This dynamic is likely due to the hormonal milieu of the
651 physiological state[5]. Lack of capturing a circadian rhythm of BMAL1 binding may have led to
652 our findings that expected targets such as *Per1* were not identified across all four samples
653 (Supplemental Figure S4g). Additionally, data were completely generated using a mammary cell
654 line, and need to be confirmed and studied *in vivo*.

655 Caution must also be used in interpreting comparisons between HC11 and BMAL1-KO
656 lines. An appropriate negative control was not used for studies as off target effects were
657 observed when the scrambled sequence was transfected into HC11 cells. Off target effects are
658 common with CRISPR-CAS [57], and so findings presented may not be specific to loss of
659 BMAL1 function. Finally, the assay used to measure reactive oxygen species level may not truly

660 be reflective of its content [58], and thus caution is warranted in interpreting these data.
661 Regardless, data presented in the manuscript will serve as a good resource to inform future
662 studies aimed at understanding the role of the mammary clock in mammary morphogenesis and
663 lactation as well as provide insight into the link between circadian disruption and breast cancer
664 and poorer milk production.

665 Overall, ChIP-seq analysis revealed potential BMAL1 transcriptional targets in mammary
666 epithelial cells. Knowledge of these targets provides insight into the role of circadian clocks in
667 undifferentiated and differentiated states of mammary epithelial cells. BMAL1 transcriptional
668 targets play central roles in pathways that affect stem cell maintenance, cellular detoxification
669 and proteostasis, substrate transport and milk fat synthesis. There was also evidence for the
670 coordination of endocrine-paracrine signals by the mammary epithelial clock, as BMAL1 targets
671 included both the ligand and corresponding receptor as in the case of prolactin, insulin and Wnts
672 with Fzd receptor. In vivo studies are now needed to understand the roles of mammary epithelial
673 clocks in stage specific development of the gland in vivo, with interaction of stromal tissue and
674 physiological context maintained.

675 **MATERIALS AND METHODS**

676 ***Routine culture and differentiation of cell cultures.***

677 HC-11 cells were routinely cultured in complete growth medium: RPMI 1640 (50-020-PC,
678 Mediatech Inc.) supplemented with 2 g/L sodium bicarbonate (S5761-500G, Sigma Life
679 Science), 100 U/mL penicillin, 100 µg/mL streptomycin (15140-122, ThermoFisher Scientific),
680 10% heat inactivated calf serum (26170-043, Gibco), 5 µg/mL insulin ([Ins] IO516-5mL, Sigma-
681 Aldrich), and 10 ng/mL epidermal growth factor ([EGF] E4127, Sigma-Aldrich) in 5% CO₂ at

682 37°C. Cells were passaged 1:3 when they reached 80% confluence by harvesting cells with
683 0.25% trypsin EDTA (Gibco).
684 To induce differentiation, cells were plated at 100,000 cells/mL and grown to confluence. At
685 confluence cells were washed 2-times with PBS, and incubated for 48 hr in RPMI media
686 supplemented with 10% serum and Ins (no EGF in media). Undifferentiated cultures (UNDIFF)
687 were harvested for downstream analysis at this stage of culture. For differentiated cultures
688 (DIFF), media was changed to RPMI supplemented with 10% calf serum, dexamethasone (0.1
689 μM), insulin (5 μg/mL), and prolactin (5 μg/mL; ovine prolactin: L6520-250IU, Sigma-Aldrich),
690 and incubated for 96 hr, with media change every 2-days. After 96 hr in lactogen cocktail,
691 differentiated cultures were collected.

692 For growth curve analysis, 100,000 cells were plated using complete growth media in 6-
693 well dishes, and cells from 2-dishes per time point were harvested using trypsin EDTA and
694 counted on days 2, 4 and 8 using a BioRad TC10 Automated cell counter (BioRad Laboratories,
695 Inc). Growth curves were conducted 5-times, and results were presented as mean number of
696 cells each day ± standard deviation. Doubling time was calculated using the tool available
697 here[59].

698 To measure circadian rhythms of gene expression, cells were grown to 80% confluence in
699 6 well plates. Media was changed to lactogen media, and cells were incubated for 2 hr at 37 °C
700 to synchronize clocks[5]. After completion of 2 hr lactogen treatment [designated as circadian
701 time 0 (CT0)], three wells of cells of each line were rinsed with PBS and RLT buffer from the
702 QIAGEN RNeasy kit was added to cultures and lysates were collected and stored at -80 °C for
703 subsequent isolation of total RNA. Cells in remaining wells were washed three-times with PBS,
704 and complete growth media was added. Beginning from CT0 and every 4 hr over the next 48 hr,

705 cells were rinsed with PBS, RLT buffer was added, and lysates collected and stored at -80 °C for
706 subsequent isolation of total RNA.

707 ***Two-and a half dimensional drip cultures and immunofluorescence***

708 RPMI growth media supplemented with 5% serum, 5 µg/mL prolactin, 5 µg/mL insulin, and
709 0.375 ng/µL hydrocortisone (cat. no. 65966, BD Biosciences) was used for 2.5-dimensional drip
710 cultures to study acini formation[60]. Briefly, cold Matrigel (Growth Factor Reduced: 356231,
711 Corning Life Sciences; 50 µL of gel/cm3) was used to coat the bottom of each well of 4-well
712 chamber plates (Lab-Tek, Nunc). The 4-well chamber plate was placed in 5% CO₂ at 37°C for 30
713 minutes to allow the Matrigel to solidify, and then cells were plated at a density of 13,000
714 cells/cm². Cells were allowed to attach Matrigel for 15 min and then media with 5% Matrigel
715 was added drop by drop to cover cultures. Media was changed every two days. On day seven of
716 cultures, images of cultures were captured at 200 X magnification (20 X objective) with phase
717 contrast on a Zeiss AxioVert (Oberkochen, Germany) inverted microscope using a Nikon
718 camera.

719 ***Creation and screening of CRISPR-CAS BMAL1 knockout HC11 lines***

720 ORIGENE's ARNTL Mouse Gene Knockout Kit (CRISPR; CAT#: KN301604; Rockville, MD
721 US) was used to knockout (remove) the BMAL1 gene from HC11 cells following
722 manufacturer's protocol. The kit contained: KN301604G1, *Arntl* gRNA vector 1 (gRNA1)
723 in pCas Guide CRISPR vector with the target sequence: GAACCGGAGAGTAGGTCGGT;
724 KN301604G2, *Arntl* gRNA vector 2 (gRNA2) in pCas Guide CRISPR vector with the target
725 sequence: CATGAAGTCGCTGATGGTTG; KN301604-D, donor DNA containing left and right
726 homologous arms and green fluorescent protein-puromycin resistance gene functional cassette;
727 and GE100003 scramble sequence in pCas-Guide vector. HC11 cultures in 6-well dishes were

728 plated overnight and transfected with the gRNA1, gRNA2 or scramble along with the donor
729 cassette using TurboFectin (Origene, cat# TF81001). Forty-eight hours post-transfection, cells
730 were split 1:10. Cells were split 1:10 a total of seven times. Transfected cells were selected for
731 using puromycin at 8 ug/mL. Monoclonal colonies were established using cloning discs soaked
732 in trypsin. Viable colonies were grown to confluence and tested for heterozygous or homozygous
733 knockout of BMAL1 using PCR and western blot analysis.

734 PCR primers used to confirm genomic integration were as follows for the left integration
735 junction: TACTAATGTAGCCCAGGATGGT (Sense) and TAGGTGCCGAAGTGGTAGAA
736 (AntiSense); right integration junction: AATGGAAGGATTGGAGCTACG (Sense)
737 and CTCAATGATCTGGATGACTTACA (AntiSense); and donor cassette
738 CAGATGCCGGTGAAGAAAGA (Sense) and GGAATGAGCTGGCCCTTAAT (AntiSense).
739 PCR amplified DNA was Sanger sequenced at Purdue University's Genomics Core.

740 Preliminary growth curve analysis studies indicated multiple monoclonal lines created
741 using scramble sequences exhibited off target effects on cell growth. Blasting the scramble
742 sequence against the mouse genome found multiple growth regulatory genes near similar
743 sequences. Alterations in coding sequence, etc., due to integration of scramble could have
744 affected these genes. Thus, a negative control was abandoned for all subsequent studies.

745 ***Fluorescence activated cell sorting (FACS) analysis of percent of proliferating cells***

746 For FACS analysis of percent proliferating cells across eight-days of culture, cells were plated at
747 a density of 100,000 cells/ml, and duplicate samples of each line were harvested on days 2, 4 and
748 8. Cells were counted and approximately 1.5×10^6 cells were pelleted by centrifugation. Cell
749 pellets of were resuspended in 100 μ l of PBS, fixed with drop-wise addition of 280 μ l of ice-cold
750 90% ethanol and stored at -20° C until day of analysis. On day of analysis, fixed cells were

751 pelleted by centrifugation and resuspended in 1ml PBS-0.5% BSA, pelleted again, resuspended
752 in PBS-0.5% BSA with 100 U/ml RNase (R6513 Sigma-Aldrich), and incubated for 15 min at
753 37°C. Five μ l of propidium iodide (PI; 500 μ g/ml stock solution) was added and cells were
754 incubated 15 minutes at RT. PI labelled cells were analysed by fluorescently activated cell
755 sorting (FACS) using a Beckman Coulter FC500 instrument in the Purdue University's Flow
756 Cytometry and Cell Separation Facility. FACS analysis was repeated 3-times.

757

758 ***MTT cell proliferation and reactive oxygen species (ROS) assays.***

759 HC11 and BMAL1-KO cells were plated in 96-well plates at 3,000 cells/well in RPMI 1640-
760 phenol free growth media. For MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
761 bromide) assay, on day 2, 4, 6, and 8 after plating (three wells per line per day), media was
762 removed from wells and cells were incubated with MTT from the Cell Proliferation Kit (Sigma
763 Aldrich, catalogue no. 11465007001), and the colorimetric assay was performed following
764 manufacturer's directions. After completion of the assay, images of cells were captured under
765 bright field at 10 X magnification with a Nikon camera attached to a Zeiss inverted microscope,
766 and absorbance was read at 540 nm on the Spark multimode microplate reader (Tecan Trading
767 AG, Switzerland). To assess relative amount of activity per cell on days 2 and 6 of culture, MTT
768 staining per unit area of cells was measured using the ColonyArea Plugin [61] to capture and
769 calculate colony intensity percent. Colony intensity percent is the ratio of the sum of pixel
770 intensities in a region to the sum of all the pixels within the same region of interest multiplied by
771 255, i.e. assuming highest intensity with full saturation of these pixels. For analysis 100
772 individual cells were selected across three images and percent intensity of staining was
773 measured. The Reactive Oxygen Species Assay Kit (Abcam catalogue No. ab113851) was used

774 to measure the level of ROS in cell lines on days 3 and 4 (three wells per line per day) after
775 plating cells, with fluorescence immediately measured at Ex/Em 485/535 nm on the Spark
776 multimode microplate reader. Both assays were performed three times.

777 ***Protein Isolation, Enzyme-linked Immunosorbent Assay (ELISA), Western Blot and***

778 ***Immunoprecipitation (IP) Analysis***

779 Protein lysates were isolated from cultures by pouring off media, washing twice with
780 chilled PBS, and harvesting using a scraper and 3 ml of cold PBS. Cells were pelleted by
781 centrifugation, and cell pellets were lysed for 30 min on ice with 600 μ l of Cell Extraction Buffer
782 (Invitrogen, supplemented with 1mM of PMSF and 50 μ l/ml of Protease Inhibitor Cocktail,
783 Sigma Aldrich), with vortexing at 10 min intervals. Protein lysates were transferred to
784 microcentrifuge tubes and centrifuged at 13,000 rpm for 10 min at 4 ° C. Protein concentration
785 was measured using a nanodrop (ThermoFischer) and the Coomassie Plus Protein Assay kit
786 (Pierce Coomassie Plus (Bradford) Protein Assay; Thermo Fisher Scientific) following the
787 manufacturer's protocol. Samples were stored at -80°C until further analysis.

788 BMAL1 (cat. no. LS-F39618) and beta-casein (CSN2, cat. no. LS-F13103) protein levels
789 in cell lysates were measured with ELISA kits from LSBio following manufacturer's directions.
790 Since number of cells and protein concentration changed with state of differentiation of cells,
791 data were expressed as micrograms of CSN2 or BMAL1 protein per mg of protein.

792 For western blot analysis, 100 μ g of protein were loaded per lane and electrophoresed on
793 a 10% TGX precast SDS PAGE gel from Bio-Rad. Protein was transferred onto a nitrocellulose
794 membrane, and membranes were blocked using either 5% BSA (Bovine Serum Albumin), and
795 probed for BMAL1, CSN2 and beta-actin proteins using anti-BMAL1 (ab3350, dilution
796 1:1,000), anti-CSN2 (LS-C373659, Life Spam, dilution 1:200) and Anti-beta-actin (AbCam

797 ab8227, dilution 1:10,000) antibodies, respectively. Blots were washed and then incubated with
798 secondary antibody (ab97051; 1:5000). Membranes were washed and incubated with the
799 detection reagent Clarity Western ECL Substrate (Bio-Rad). Blots were imaged using the
800 ChemiDoc MP system (BioRad). ImageJ was used for densitometric analysis. Density of test
801 protein (BMAL1 and CSN2) were divided by density of beta-actin (BA) band. To enable
802 statistical analysis across multiple gels run to measure CSN2 protein levels, ratio was normalized
803 to relative expression of HC11 UNDIFF.

804 For IP analysis of specificity of ChIP grade antibody BMAL1 (Abcam; ab3350), rabbit
805 polyclonal antibody to BMAL1 (Abcam; ab3350) was added to 200 µg protein in 200 µl cold
806 PBST (PBS pH 7.4 with 0.02% Tween-20), and rotated overnight at 4° C. The antibody protein
807 mixture was added to Dynabeads protein A for immunoprecipitation (ThermoFischer) and
808 pipetted gently to resuspend. Samples were rotated for 2 hr at 4° C. Tubes were placed on
809 magnetic rack to pellet beads, and washed three times with 200 µl cold PBS. Then 15 µl PBS
810 and 15 µl 2X Laemmli sample buffer with 2-mercaptoethanol added per manufacturer's
811 instructions, and gently pipetted to resuspend. Samples were heat at 100° C for 5 min and placed
812 on magnetic rack to pellet beads. Supernatant was removed and separated using SDS-Page gel
813 for analysis by western blot. Mouse monoclonal BMAL1 antibody (Santa Cruz Biotechnology,
814 Inc., Dallas, TX US; cat. no. sc-365645) was used for western blot analysis.

815 ***RNA Isolation and Real-Time Quantitative PCR Analysis (RT-qPCR)***

816 RNA was collected from cells and isolated using Qiagen's RNeasy kit with an on-column
817 DNase treatment, and quantity was measured using Nanodrop. RIN scores of total RNA
818 following nanochip analysis on an Agilent 2100 Bioanalyzer were found to vary from 8.0-9.0
819 across all samples. Promega's GoScript Reverse Transcriptase kit was used to reverse transcribe

820 500 ng of total RNA into cDNA following manufacturer's protocol. Gene expression was
821 analysed with TaqMan Assays on Demand using 2× TaqMan Gene Expression Master Mix
822 (Life Technologies) using a 1:10 dilution of the cDNA product. The CFX Connect Real-Time
823 PCR Detection System (BioRad) was used to run RTq-PCR, which was initiated with 2 min
824 incubation at 95°C and then 40 cycles of 95°C for 15 sec and 60°C for 1min, and standby was set
825 at 4°C. Multiple genes (beta-actin, beta microglobulin and 18S) were screened as reference genes
826 (housekeeping gene) for calculating relative expression using the $2^{-\Delta\Delta CT}$ method [62]; 18S was
827 chosen as the reference gene based on its levels staying steady across time and genotype. Mouse-
828 specific Assay on Demand TaqMan assays (Life Technologies) used were *Per2*
829 (Mm00478099_m1), *Sod3* (Mm01213380_s1), *Csn2* (Mm04207885_m1), *Tph1*
830 (Mm01202614_m1), *Slc6a4* (SERT, Mm00439391_m1), *Ccnd1* (Mm00432359_m1), *Ppara*
831 (Mm00440939_m1), *Prlr* (Mm04336676_m1), and *18S*. To calculate relative expression, mean
832 ΔCT of wild-type HC11 UNDIFF cultures was used as normalizer for relative expression. For
833 temporal analysis of *Per2* expression across 48 hr sampling mean ΔCT of HC11 cultures across
834 all time was used as the normalizer for relative expression. Data are presented as mean fold-
835 change \pm standard deviation of relative expression levels, or mean of log base two-fold change \pm
836 standard deviation for *Csn2* expression.

837 ***ChIP assay and q-PCR verification of known targets.***

838 Use of two independent biological replicates for ChIP-seq analysis to identify
839 transcriptional targets is consistent with ENCODE (Encyclopaedia of DNA Elements)
840 guidelines[63]. For ChIP-seq studies, we performed four independent ChIP experiments, two
841 with undifferentiated cultures and two for differentiated cultures, to enable analysis of the effect
842 of differentiation on BMAL1 targets. Briefly, undifferentiated and differentiated HC11 cultures

843 in 100 mm plates were treated with 1% formaldehyde to cross-link proteins to chromatin by
844 adding 625 μ l fresh 16% formaldehyde directly to the dishes containing cells and 10 mL media,
845 and incubated at RT on a shaking platform for 7 min. To quench the formaldehyde, 500 μ l of
846 2.5M glycine was added, and incubated at RT on the shaking platform for 5 min. Cells were
847 washed twice with ice cold PBS, and removed from culture dish using a cell scraper. Cells were
848 pelleted by centrifugation and stored at the -80 °C. Samples were collected for ChIP assays in
849 four replicate experiments (sample IDs UNDIFF1, UNDIFF2, DIFF1, DIFF2).

850 Nuclei were collected by resuspending each fixed-cell pellet in 10 mL of Rinse 1 (50mM
851 Hepes pH 8.0, 140mM NaCl, 1mM EDTA, 10% glycerol, .5% NP40, .25% Triton x100), and
852 incubating 10 min on ice. Samples were pelleted by centrifugation 1,200 X g at 4 °C for 5 min,
853 and then resuspend in 10 mL CiA NP-Rinse 2 (10mM Tris pH 8.0, 1mM EDTA, 0.5mM EGTA,
854 200mM NaCl), and then centrifuged at 1,200 X g and 4 °C for 5 min. Pellets were washed with
855 5 ml of CiA Covaris Shearing Buffer (0.1% SDS, 1mM EDTA pH 8.0, 10mM Tris HC1 pH 8.0)
856 twice with centrifugation at 1,200 X g and 4 °C for 3 min after each wash. For sonication, pellets
857 from approximately 3 million cells each were resuspended in 130 μ l of CiA Covaris Shearing
858 Buffer with 10% protease inhibitor cocktail. Pellets were sonicated in a Covaris E210
859 instrument (Covaris, Inc., Woburn, MA) using the following parameters: Duty Factor 5%, Peak
860 power 105W, Cycles per burst 200, 10 min. Following sonication sheared chromatin lysate was
861 transferred to a new centrifuged at 20,000 X g and 4 °C for 15 min. Supernatant (sheared
862 chromatin stock) was divided into three aliquots for input DNA, mock-immunoprecipitation (IP)
863 and IP and stored at -80 °C (-20C), after removal of an aliquot for analysis of product size in a
864 2% agarose gel and on the Agilent Bioanalyzer Nanochip.

865 For immunoprecipitation step, cross-linked chromatin using anti-BMAL1 antibody and
866 mock-IP aliquots were thawed on ice. Samples were precleared by adding 50 μ L resuspended A
867 beads (DynaBeads Protein A, Invitrogen cat. # 10001D), and incubating at 4° C for 1.5 hr with
868 rotation. Tubes were placed on a magnetic rack and liquid was transferred to a new microfuge
869 tube. One-quarter of the volume of 5X IP Buffer (250mM Hepes/KOH pH 7.5, 1.5M NaCl,
870 5mM EDTA, 5% TritonX 100, 0.5% DOC [4-chloro-2,5-dimethoxy-amphetamine], 0.5% SDS)
871 was added, and 10 μ L of BMAL1 antibody (Abcam ab 3350) was added to IP tube, and nothing
872 was added to mock-IP tube. Samples were rotated overnight at 4° C, and then 50 μ L of
873 resuspended A beads were added to each tube, and rotated for 3 hr at 4° C. Magnetic rack was
874 used to remove A beads. Supernatant was collected transferred to a new tube, and washed with
875 1mL IP Buffer twice with rotation at RT for 3 min, and collection on magnetic rack following
876 wash. Supernatants were then washed with 1 mL of DOC buffer (10 mM Tris, pH8.0; 0.25 M 1
877 (iCl; 0.5% NP40, 0.5% DOC, 1 mM EDTA), followed by 1 mL of Tris EDTA (TE) buffer pH 8.
878 Supernatant was removed and 150 μ L elution buffer was added and samples were rotated at RT
879 for 20 min. Supernatant was transferred to a new tube and store at -80 °C until DNA isolation.

880 Chromatin was isolated from supernatant by adding 3 volumes of TE with 1% SDS and
881 RNase A (Sigma R6513), and vortexing to mix. Samples were incubated at 37° C for 30 min,
882 and proteinase K was added, vortexed again to mix, and cross-linking was reversed by
883 incubating at 55° C for ~2.5 hr, and then overnight at 65° C in PCR tubes in the thermocycler.
884 DNA was extracted the next day by adding 230 μ L TE and 330 μ L phenol/chloroform,
885 vortexing, followed by centrifugation for 1 min. Aqueous layer was transferred into a new
886 microfuge tube and 10 μ L of commercial glycogen (ThermoScientific R0551) was added with 30
887 μ L 3M NaCl. One volume of 100% ethanol was added and samples vortexed to mix. Samples

888 were incubated for two days at -20 ° C, and then centrifuged 1 hr at 4 °C to pellet DNA. Pellet
889 was washed twice by removing the supernatant and adding 500 µl 70% EtOH. Pellet was
890 resuspended in 25 µL TE and concentration was measured with Qubit fluorometer (Thermo
891 Fisher Scientific) and a Bioanalyzer 2100 (Agilent), and samples stored at -80° C until
892 sequencing.

893 To determine specificity BMAL1 antibody, qPCR analysis of ChIP product, input and
894 mock-IP samples were performed using primers designed to target the promoter region of *Per1*,
895 a transcriptional target of BMAL1: CLOCK, and the exon region of a mouse sperm gene
896 *Mageal_2*, which was not expected to be a target of BMAL1 binding. The promoter region of
897 *Per1* containing the proximal E-box enhancer was amplified with the following primer set:
898 forward, 5-CCTCCCTGAAAAGGGGTA-3; reverse, 5-GGATCTCTCCTGGCATCTG-3.
899 Primers used to amplify *MAGEA1_2*, with forward: 5-GCCTCTGAGTGCTTGAAAGAT-3, and
900 reverse: 5-CAGGGCAGTGACAAGGATATAG-3. Primers were designed to promoter regions
901 of SLC6A4 (aka SERT) to encompass an E-box most proximal (beginning at -42 nucleotides) to
902 the transition start site forward: 5- CTCCAGCTGCGGTAGCAGA-3 and reverse: 5-
903 ATTTGTACTTGCGGCC-3, and more distal (beginning at -1282 nucleotides) Forward: 5-
904 GGAGTTACAGGCACGGAAG-3 and reverse 5-GCCTGGCCATTCCATGA-3. Triplicate
905 samples were measured using SYBR green real-time PCR master mix (ThermoFischer
906 Scientific). The analysis was conducted using the CFX Connect Realtime PCR Detection
907 System (Biorad) with the following conditions for reactions were 1 cycle at 50°C for 2 min; 1
908 cycle at 95°C for 2 min, 55 cycles at 95°C for 15 sec, gradient 58-60°C for 30 sec and 72 °C for
909 1min; and 1 cycle at 95°C for 10 sec, melt curve 65°C – 95°C, increment 0.5°C for 5 sec. PCR

910 reaction efficiencies were 98% at annealing temperature 58°C for *Per1* and *Sert*, and at 60°C the
911 efficiency for *Magea1* was 96%.

912 To calculate relative amount of input target brought down by ChIP with BMAL1
913 antibody the following equation was use: adjusted input sample- C_T of ChIP sample
914 (<https://www.thermofisher.com/us/en/home/life-science/epigenetics-noncoding-rna-research/chromatin-remodeling/chromatin-immunoprecipitation-chip/chip-analysis.html>). A
915 positive ChIP was defined as at least 2-fold greater than mock-IP sample [64].
916

917 ***Sequencing of DNA, peak identification, and functional annotation analysis***

918 Input and ChIP sample pairs were sequenced together by paired ends reads on the Illumina
919 Novaseq 6000 (San Diego, CA) following the manufacturer's protocols. Prior to sequencing
920 libraries were prepared using NEXTFLEX Rapid DNA-Seq Library Prep Kit for
921 Illumina Platforms (PerkinElmer, Waltham, MA) according to manufacturer's protocol. The
922 number of reads for three of the input ChIP sample pairs (both UNDIFF samples and one DIFF
923 sample) averaged approximately 100 million reads. The remaining DIFF input-ChIP pair had
924 over 1 billion reads. To account for discrepancy in depth of sequencing, the reads were divided
925 into five groups, and one group of input-ChIP sample pair was used for analysis. Sequence
926 quality was assessed using FastQC (v 0.11.7) for all samples and quality trimming was done
927 using Fastx toolkit to remove bases with Phred33 score of less than 30. The resulting reads of
928 length at least 50 bases were retained. The quality trimmed reads were mapped against the
929 reference genome (Mus_musculus.GRCm38.chr.fa) using bowtie2 (Version 2.2.9)[65]. ChIP-seq
930 data were submitted to Gene Expression Omnibus (GEO accession number GSE154937).

931 Peaks were called from mapped files (bam files) using 'callpeaks' script of HOMER
932 (Version 4.10)[66] to detect transcription factor associated peaks using default settings except for

933 the following parameters: fold enrichment over input tag count (F) was set at 2, fold enrichment
934 limit of expected unique tag positions (C) was set at 2 and fold enrichment over local tag count
935 (L) was set at 2 and FDR was set at <0.01. Quality control analyses were run from files
936 generated in read tag directories to include tag count distribution, autocorrelation analysis,
937 genomic nucleotide frequency relative to read positions, and fragment GC % distribution, met
938 criteria for further analysis. Picard Mark Duplicates was performed on each sample
939 (Supplemental Table S18). Common nearest gene associated with peaks between UNDIFF1 and
940 UNDIFF2, DIFF1 and DIFF2 were generated using Venny 2.1[67].

941 Overlap of BMAL1 targets in HC11 cells with genes that exhibit circadian rhythms of
942 gene expression in virgin mouse mammary glands[13] and in human breasts during lactation[14]
943 was investigated by obtaining supplemental data from these manuscripts. Similarly, overlap of
944 HC11 BMAL1 targets with BMAL1 transcriptional targets identified in mouse liver was also
945 investigated by obtaining supplemental data this manuscript[19]. For comparative analysis, gene
946 symbols were converted to mouse ENSEMBL IDs using the gene conversion tool available in
947 DAVID, and then common genes across data sets were identified using Venny 2.1[67].

948 Functional annotation analysis was performed using Database for Annotation,
949 Visualization, and Integrated Discovery-DAVID Bioinformatic Resources 6.8[68, 69], and
950 Ingenuity Pathway Analysis (IPA; QIAGEN Inc.,
951 <https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis>). To aid in
952 visualization of IPA generated figures, genes were assigned a value of 5 and were indicated as
953 red in figure of Regulator Networks. The network with highest consistency score was used, with
954 the higher scores reflecting paths between target gene and output function consistent with the
955 predicted state of the regulator—here all indicated as upregulated--based on the literature. IPA

956 predicted upstream regulators were removed from the generated network, as BMAL1 was the
957 upstream regulator (Supplemental Figure S2). The My Pathway tools in IPA was used for
958 visualization of a subset of BMAL1 target genes. GeneCards [70] was used to query information
959 on function of genes of interest.

960 ***Statistical analysis***

961 Statistical analysis was performed using SPSS software (IBM SPSS, v.26). General linear model
962 was used to analyze whether cell line (HC11 or BMAL1-KO) or state of differentiation (DIFF or
963 UNDIFF), or day (growth curve, MTT assay, ROS assay, and FACS analysis) significantly
964 impacted variables (relative expression, protein abundance, doubling time, and cell density). A
965 Tukey's post-hoc test was used for pairwise comparisons. Significance was considered at $P \leq$
966 0.05. Cosine fit analysis of 24 hr rhythms of gene expression was performed with the cosinor
967 package in R (RStudio 1.1.453, Boston, MA). Mesor, amplitude, acrophase R^2 , and p -value were
968 outputs of the package algorithm.

969

970

971

972

973

974

975 **Acknowledgements.** The authors would like to thank Paul Parker for analysis of ChIP samples,
976 and Shaojun Xie for reading and editing manuscript.

977 **Conflict of Interests Statement.** The authors declare no competing interests.

978 **Authors' contributions.** TC: conceived ideas, designed studies, analyzed data, wrote
979 manuscript; AT: conceived ideas, designed and conducted studies, analyzed data, edited and
980 approved manuscript, SC: designed and conducted studies, analyzed data, edited and approved
981 manuscript; KH: designed and conducted studies, analyzed data, edited and approved
982 manuscript; JC: designed and conducted studies, analyzed data, edited and approved manuscript;
983 KB designed and conducted studies, analyzed data, edited and approved manuscript; CA:
984 designed and conducted studies, analyzed data, edited and approved manuscript, KT: conducted
985 studies, analyzed data, edited and approved manuscript; AS: conceived ideas, designed studies,
986 edited and approved manuscript; SM: conceived ideas, designed studies, edited and approved
987 manuscript; PSM: designed and conducted studies, analyzed data, edited and approved
988 manuscript; JT: designed and conducted studies, analyzed data, edited and approved manuscript,
989 KP: conceived ideas, designed studies, edited and approved manuscript. All authors approved
990 the manuscript.

991 **Data availability statement.** ChIP-seq were made publicly available through Gene Expression
992 Omnibus (GEO) and can be found using the following accession number GSE154937. All other
993 data will be made available upon request to corresponding author.

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

REFERENCES

1006

1007

1008 1. Eckel-Mahan K, Sassone-Corsi P. Metabolism and the circadian clock converge.

1009 Physiological Reviews. 2013;93(1):107-35. doi: 10.1152/physrev.00016.2012. PubMed PMID:

1010 WOS:000313562300004.

1011 2. Masri S, Zocchi L, Katada S, Mora E, Sassone-Corsi P. The circadian clock

1012 transcriptional complex: metabolic feedback intersects with epigenetic control. Annals of the

1013 New York Academy of Sciences. 2012;1264(1):103-9. doi: 10.1111/j.1749-6632.2012.06649.x.

1014 3. Gérard C, Goldbeter A. Entrainment of the Mammalian Cell Cycle by the Circadian

1015 Clock: Modeling Two Coupled Cellular Rhythms. PLoS Comput Biol. 2012;8(5):e1002516. doi:

1016 10.1371/journal.pcbi.1002516.

1017 4. Metz R, Qu X, Laffin B, Earnest DJ, Porter W. Circadian clock and cell cycle gene

1018 expression in mouse mammary epithelial cells and in the developing mouse mammary gland.

1019 Developmental Dynamics. 2006;235(1):263-71.

1020 5. Casey TM, Crodian J, Erickson E, Kuropatwinski KK, Gleiberman AS, Antoch MP.

1021 Tissue-Specific Changes in Molecular Clocks During the Transition from Pregnancy to Lactation

1022 in Mice. Biology of Reproduction. 2014;90(6):127. doi: 10.1095/biolreprod.113.116137.

1023 6. Hardin PE. Transcription Regulation within the Circadian Clock: The E-box and Beyond.

1024 J Biol Rhythms. 2004;19(5):348-60. doi: 10.1177/0748730404268052.

1025 7. Akhtar RA, Reddy AB, Maywood ES, Clayton JD, King VM, Smith AG, et al. Circadian

1026 Cycling of the Mouse Liver Transcriptome, as Revealed by cDNA Microarray, Is Driven by the

1027 Suprachiasmatic Nucleus. Current Biology. 2002;12(7):540-50.

1028 8. Panda S. Coordinated transcription of key pathways in the mouse by the circadian clock.

1029 Cell. 2002;109:307-20.

1030 9. Storch KF. Extensive and divergent circadian gene expression in liver and heart. Nature.

1031 2002;417:78-83.

1032 10. Albrecht U. Timing to Perfection: The Biology of Central and Peripheral Circadian

1033 Clocks. Neuron. 2012;74(2):246-60. doi: <http://dx.doi.org/10.1016/j.neuron.2012.04.006>.

1034 11. Duffield GE, Best JD, Meurers BH, Bittner A, Loros JJ, Dunlap JC. Circadian Programs

1035 of Transcriptional Activation, Signaling, and Protein Turnover Revealed by Microarray Analysis

1036 of Mammalian Cells. Current Biology. 2002;12(7):551-7.

1037 12. Reddy AB, Karp NA, Maywood ES, Sage EA, Deery M, O'Neill JS, et al. Circadian

1038 Orchestration of the Hepatic Proteome. Current Biology. 2006;16(11):1107-15.

1039 13. Yang N, Williams J, Pekovic-Vaughan V, Wang P, Olabi S, McConnell J, et al. Cellular

1040 mechano-environment regulates the mammary circadian clock. Nat Commun. 2017;8:14287.

1041 Epub 2017/01/31. doi: 10.1038/ncomms14287. PubMed PMID: 28134247; PubMed Central

1042 PMCID: PMCPMC5290282.

1043 14. Maningat PD, Sen P, Rijnkels M, Sunehag AL, Hadsell DL, Bray M, et al. Gene

1044 expression in the human mammary epithelium during lactation: the milk fat globule

1045 transcriptome. *Physiological Genomics*. 2009;37(1):12-22. doi:
1046 10.1152/physiolgenomics.90341.2008.

1047 15. Dolatshad H, Campbell EA, O'Hara L, Maywood ES, Hastings MH, Johnson MH.
1048 Developmental and reproductive performance in circadian mutant mice. *Human Reproduction*.
1049 2006;21(1):68-79. doi: 10.1093/humrep/dei313.

1050 16. Kennaway DJ BM, Voultis A. Reproductive performance in female Clock(Delta19)
1051 mutant mice. *Reprod Fertil Dev*. 2004;16(8):801-10.

1052 17. Hoshino K, Wakatsuki Y, Iigo M, Shibata S. Circadian Clock Mutation in Dams Disrupts
1053 Nursing Behavior and Growth of Pups. *Endocrinology*. 2006;147(4):1916-23. doi:
1054 10.1210/en.2005-1343.

1055 18. Casey T, Crodian J, Suarez-Trujillo A, Erickson E, Weldon B, Crow K, et al. CLOCK
1056 regulates mammary epithelial cell growth and differentiation. *Am J Physiol Regul Integr Comp
1057 Physiol*. 2016;311(6):R1125-R34. Epub 2016/10/07. doi: 10.1152/ajpregu.00032.2016. PubMed
1058 PMID: 27707717; PubMed Central PMCID: PMCPMC5256977.

1059 19. Rey G, Cesbron F, Rougemont J, Reinke H, Brunner M, Naef F. Genome-Wide and
1060 Phase-Specific DNA-Binding Rhythms of BMAL1 Control Circadian Output Functions in
1061 Mouse Liver. *PLoS Biol*. 2011;9(2):e1000595. doi: 10.1371/journal.pbio.1000595.

1062 20. Kondratov RV, Kondratova AA, Gorbacheva VY, Vykhovanets OV, Antoch MP. Early
1063 aging and age-related pathologies in mice deficient in BMAL1, the core component of the
1064 circadian clock. *Genes & development*. 2006;20(14):1868-73. doi: 10.1101/gad.1432206.
1065 PubMed PMID: 16847346.

1066 21. Mroue R, Bissell MJ. Three-Dimensional Cultures of Mouse Mammary Epithelial Cells.

1067 In: Randell SH, Fulcher ML, editors. *Epithelial Cell Culture Protocols*: Second Edition. Totowa,

1068 NJ: Humana Press; 2013. p. 221-50.

1069 22. Hoffman JA, Trotter KW, Ward JM, Archer TK. BRG1 governs glucocorticoid receptor

1070 interactions with chromatin and pioneer factors across the genome. *Elife*. 2018;7:e35073. doi:

1071 10.7554/eLife.35073.

1072 23. Paakinaho V, Johnson TA, Presman DM, Hager GL. Glucocorticoid receptor quaternary

1073 structure drives chromatin occupancy and transcriptional outcome. *Genome Res*.

1074 2019;29(8):1223-34. Epub 2019/07/23. doi: 10.1101/gr.244814.118. PubMed PMID: 31337711.

1075 24. Lkhider M, Delpal S, Le Provost F, Ollivier-Bousquet M. Rat prolactin synthesis by

1076 lactating mammary epithelial cells. *FEBS Letters*. 1997;401(2):117-22. doi:

1077 [https://doi.org/10.1016/S0014-5793\(96\)01450-0](https://doi.org/10.1016/S0014-5793(96)01450-0).

1078 25. Kang K, Yamaji D, Yoo KH, Robinson GW, Hennighausen L. Mammary-specific gene

1079 activation is defined by progressive recruitment of STAT5 during pregnancy and the

1080 establishment of H3K4me3 marks. *Mol Cell Biol*. 2014;34(3):464-73. Epub 2013/11/25. doi:

1081 10.1128/MCB.00988-13. PubMed PMID: 24277936.

1082 26. Lee Y, Lee J, Kwon I, Nakajima Y, Ohmiya Y, Son GH, et al. Coactivation of the

1083 CLOCK-BMAL1 complex by CBP mediates resetting of the circadian clock. *J Cell Sci*.

1084 2010;123(Pt 20):3547-57. Epub 2010/10/12. doi: 10.1242/jcs.070300. PubMed PMID:

1085 20930143.

1086 27. Travnickova-Bendova Z, Cermakian N, Reppert SM, Sassone-Corsi P. Bimodal

1087 regulation of *mPeriod* promoters by CREB-dependent signaling and

1088 CLOCK/BMAL1 activity. *Proceedings of the National Academy of Sciences*. 2002;99(11):7728-

1089 33. doi: 10.1073/pnas.102075599.

1090 28. Golombek DA, Rosenstein RE. *Physiology of Circadian Entrainment*. *Physiological*

1091 *Reviews*. 2010;90(3):1063-102. doi: 10.1152/physrev.00009.2009. PubMed PMID: 20664079.

1092 29. Rangel MC, Bertolette D, Castro NP, Klauzinska M, Cuttitta F, Salomon DS.

1093 Developmental signaling pathways regulating mammary stem cells and contributing to the

1094 etiology of triple-negative breast cancer. *Breast cancer research and treatment*. 2016;156(2):211-

1095 26. Epub 2016/03/11. doi: 10.1007/s10549-016-3746-7. PubMed PMID: 26968398.

1096 30. Janich P, Pascual G, Merlos-Suárez A, Batlle E, Ripperger J, Albrecht U, et al. The

1097 circadian molecular clock creates epidermal stem cell heterogeneity. *Nature*.

1098 2011;480(7376):209-14. Epub 2011/11/15. doi: 10.1038/nature10649. PubMed PMID:

1099 22080954.

1100 31. Gimble JM, Floyd ZE, Bunnell BA. The 4th dimension and adult stem cells: Can timing

1101 be everything? *J Cell Biochem*. 2009;107(4):569-78. doi: 10.1002/jcb.22153. PubMed PMID:

1102 19384905.

1103 32. Sarkar A, Hochedlinger K. The sox family of transcription factors: versatile regulators of

1104 stem and progenitor cell fate. *Cell stem cell*. 2013;12(1):15-30. doi: 10.1016/j.stem.2012.12.007.

1105 PubMed PMID: 23290134.

1106 33. Shennan DB. Mammary gland membrane transport systems. *Journal of mammary gland*

1107 *biology and neoplasia*. 1998;3(3):247-58. Epub 2000/05/20. doi: 10.1023/a:1018759326200.

1108 PubMed PMID: 10819512.

1109 34. Patel OV, Casey T, Plaut K. Profiling solute-carrier transporters in key metabolic tissues

1110 during the postpartum evolution of mammary epithelial cells from nonsecretory to secretory.

1111 Physiol Genomics. 2019;51(11):539-52. Epub 2019/09/24. doi:
1112 10.1152/physiolgenomics.00058.2019. PubMed PMID: 31545931.

1113 35. Tuszynski J, Tilli TM, Levin M. Ion Channel and Neurotransmitter Modulators as
1114 Electroceutical Approaches to the Control of Cancer. Curr Pharm Des. 2017;23(32):4827-41.
1115 doi: 10.2174/1381612823666170530105837. PubMed PMID: 28554310.

1116 36. Coloff Jonathan L, Murphy JP, Braun Craig R, Harris Isaac S, Shelton Laura M, Kami K,
1117 et al. Differential Glutamate Metabolism in Proliferating and Quiescent Mammary Epithelial
1118 Cells. Cell Metabolism. 2016;23(5):867-80. doi: 10.1016/j.cmet.2016.03.016.

1119 37. Feillet C, van der Horst GTJ, Levi F, Rand DA, Delaunay F. Coupling between the
1120 Circadian Clock and Cell Cycle Oscillators: Implication for Healthy Cells and Malignant
1121 Growth. Frontiers in neurology. 2015;6(96). doi: 10.3389/fneur.2015.00096.

1122 38. Walther DM, Kasturi P, Zheng M, Pinkert S, Vecchi G, Ciryam P, et al. Widespread
1123 Proteome Remodeling and Aggregation in Aging *C. elegans*. Cell. 2015;161(4):919-32. Epub
1124 2015/05/11. doi: 10.1016/j.cell.2015.03.032. PubMed PMID: 25957690; PubMed Central
1125 PMCID: PMCPMC4643853.

1126 39. Miller BF, Drake JC, Naylor B, Price JC, Hamilton KL. The measurement of protein
1127 synthesis for assessing proteostasis in studies of slowed aging. Ageing Research Reviews.
1128 2014;18:106-11. doi: <https://doi.org/10.1016/j.arr.2014.09.005>.

1129 40. Marshall AM, Hernandez LL, Horseman ND. Serotonin and Serotonin Transport in the
1130 Regulation of Lactation. Journal of mammary gland biology and neoplasia. 2014;19(1):139-46.
1131 doi: 10.1007/s10911-013-9304-6.

1132 41. Suárez-Trujillo A, Casey TM. Serotonergic and circadian systems: driving mammary
1133 gland development and function. *Frontiers in Physiology*. 2016;7. doi:
1134 10.3389/fphys.2016.00301.

1135 42. Bailey SM, Udo US, Young ME. Circadian regulation of metabolism. *J Endocrinol.*
1136 2014;222(2):R75-96. Epub 2014/06/15. doi: 10.1530/joe-14-0200. PubMed PMID: 24928941;
1137 PubMed Central PMCID: PMC4109003.

1138 43. Mohammad MA, Haymond MW. Regulation of lipid synthesis genes and milk fat
1139 production in human mammary epithelial cells during secretory activation. *American Journal of*
1140 *Physiology-Endocrinology and Metabolism*. 2013;305(6):E700-E16. doi:
1141 10.1152/ajpendo.00052.2013. PubMed PMID: 23880316.

1142 44. Palombo V, Loor JJ, D'Andrea M, Vailati-Riboni M, Shahzad K, Krogh U, et al.
1143 Transcriptional profiling of swine mammary gland during the transition from colostrogenesis to
1144 lactogenesis using RNA sequencing. *BMC Genomics*. 2018;19(1):322. doi: 10.1186/s12864-
1145 018-4719-5.

1146 45. Oosterman JE, Kalsbeek A, Fleur SEL, Belsham DD. Impact of nutrients on circadian
1147 rhythmicity. *Am J Physiol Regul Integr Comp Physiol*. 2015;308 5:R337-50.

1148 46. Salfer IJ, Harvatine KJ. Night-restricted feeding of dairy cows modifies daily rhythms of
1149 feed intake, milk synthesis and plasma metabolites compared with day-restricted feeding. *British*
1150 *Journal of Nutrition*. 2020;123(8):849-58. Epub 2020/01/08. doi: 10.1017/S0007114520000057.

1151 47. Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, et al. New
1152 hepatic fat activates PPARA to maintain glucose, lipid, and cholesterol homeostasis. *Cell*
1153 *Metabolism*. 2005;1(5):309-22. doi: 10.1016/j.cmet.2005.04.002.

1154 48. Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RRV, Xu HE, Turk J, et al. Identification
1155 of a physiologically relevant endogenous ligand for PPAR α in liver. *Cell*. 2009;138(3):476-
1156 88. Epub 2009/07/30. doi: 10.1016/j.cell.2009.05.036. PubMed PMID: 19646743.

1157 49. Rotman N, Wahli W. Fatty Acid Synthesis and PPAR α Hand in Hand. *Chemistry &*
1158 *Biology*. 2009;16(8):801-2. doi: <https://doi.org/10.1016/j.chembiol.2009.08.004>.

1159 50. Rakhshandehroo M, Knoch B, Müller M, Kersten S. Peroxisome proliferator-activated
1160 receptor alpha target genes. *PPAR Res*. 2010;2010:612089. Epub 2010/09/26. doi:
1161 10.1155/2010/612089. PubMed PMID: 20936127.

1162 51. Shin HY, Hennighausen L, Yoo KH. STAT5-Driven Enhancers Tightly Control
1163 Temporal Expression of Mammary-Specific Genes. *Journal of mammary gland biology and*
1164 *neoplasia*. 2019;24(1):61-71. Epub 2018/10/18. doi: 10.1007/s10911-018-9418-y. PubMed
1165 PMID: 30328555.

1166 52. Gloushankova NA, Rubtsova SN, Zhitnyak IY. Cadherin-mediated cell-cell interactions
1167 in normal and cancer cells. *Tissue Barriers*. 2017;5(3):e1356900. Epub 2017/08/08. doi:
1168 10.1080/21688370.2017.1356900. PubMed PMID: 28783415; PubMed Central PMCID:
1169 PMCPMC5571778.

1170 53. Gerber A, Esnault C, Aubert G, Treisman R, Pralong F, Schibler U. Blood-borne
1171 circadian signal stimulates daily oscillations in actin dynamics and SRF activity. *Cell*.
1172 2013;152(3):492-503. Epub 2013/02/05. doi: 10.1016/j.cell.2012.12.027. PubMed PMID:
1173 23374345.

1174 54. Horseman ND, Collier RJ. Serotonin: a local regulator in the mammary gland epithelium.
1175 *Annu Rev Anim Biosci*. 2014;2:353-74. Epub 2014/11/11. doi: 10.1146/annurev-animal-022513-
1176 114227. PubMed PMID: 25384147.

1177 55. Cooper JM, Halter KA, Prosser RA. Circadian rhythm and sleep-wake systems share the
1178 dynamic extracellular synaptic milieu. *Neurobiol Sleep Circadian Rhythms*. 2018;5:15-36. Epub
1179 2018/04/17. doi: 10.1016/j.nbscr.2018.04.001. PubMed PMID: 31236509; PubMed Central
1180 PMCID: PMCPMC6584685.

1181 56. Rey G, Cesbron F, Rougemont J, Reinke H, Brunner M, Naef F. Genome-Wide and
1182 Phase-Specific DNA-Binding Rhythms of BMAL1 Control Circadian Output Functions in
1183 Mouse Liver. *PLOS Biology*. 2011;9(2):e1000595. doi: 10.1371/journal.pbio.1000595.

1184 57. Zhang X-H, Tee LY, Wang X-G, Huang Q-S, Yang S-H. Off-target Effects in
1185 CRISPR/Cas9-mediated Genome Engineering. *Molecular Therapy - Nucleic Acids*. 2015;4:e264.
1186 doi: <https://doi.org/10.1038/mtna.2015.37>.

1187 58. Kalyanaraman B, Darley-Usmar V, Davies KJA, Dennery PA, Forman HJ, Grisham MB,
1188 et al. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and
1189 limitations. *Free Radic Biol Med*. 2012;52(1):1-6. Epub 2011/10/02. doi:
1190 10.1016/j.freeradbiomed.2011.09.030. PubMed PMID: 22027063.

1191 59. V R. <http://www.doubling-time.com/compute.php>. 2006.

1192 60. Vidi PA, Bissell MJ, Lelièvre SA. Three-dimensional culture of human breast epithelial
1193 cells: the how and the why. *Methods Mol Biol*. 2013;945:193-219. Epub 2012/10/26. doi:
1194 10.1007/978-1-62703-125-7_13. PubMed PMID: 23097109; PubMed Central PMCID:
1195 PMCPMC3666567.

1196 61. Guzmán C, Bagga M, Kaur A, Westermark J, Abankwa D. ColonyArea: an ImageJ
1197 plugin to automatically quantify colony formation in clonogenic assays. *PloS one*.
1198 2014;9(3):e92444-e. doi: 10.1371/journal.pone.0092444. PubMed PMID: 24647355.

1199 62. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time
1200 Quantitative PCR and the 2-[Delta][Delta]CT Method. *Methods*. 2001;25(4):402-8.

1201 63. Landt SG, Marinov GK, Kundaje A, Kheradpour P, Pauli F, Batzoglou S, et al. ChIP-seq
1202 guidelines and practices of the ENCODE and modENCODE consortia. *Genome Res*.
1203 2012;22(9):1813-31. doi: 10.1101/gr.136184.111.

1204 64. Tantin D, Voth WP, Shakya A. Efficient chromatin immunoprecipitation using limiting
1205 amounts of biomass. *J Vis Exp*. 2013;(75):e50064-e. doi: 10.3791/50064. PubMed PMID:
1206 23665589.

1207 65. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods*.
1208 2012;9(4):357-9. Epub 2012/03/06. doi: 10.1038/nmeth.1923. PubMed PMID: 22388286;
1209 PubMed Central PMCID: PMCPMC3322381.

1210 66. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of
1211 lineage-determining transcription factors prime cis-regulatory elements required for macrophage
1212 and B cell identities. *Mol Cell*. 2010;38(4):576-89. Epub 2010/06/02. doi:
1213 10.1016/j.molcel.2010.05.004. PubMed PMID: 20513432; PubMed Central PMCID:
1214 PMCPMC2898526.

1215 67. Oliveros, J.C. (2007-2015) Venny. An interactive tool for comparing lists with Venn's
1216 diagrams. <https://bioinfogp.cnb.csic.es/tools/venny/index.html>.

1217 68. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large
1218 gene lists using DAVID bioinformatics resources. *Nat Protoc*. 2009;4(1):44-57. PubMed PMID:
1219 19131956.

1220 69. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward
1221 the comprehensive functional analysis of large gene lists. *Nucleic acids research*. 2009;37(1):1-

1222 13. Epub 2008/11/27. doi: 10.1093/nar/gkn923. PubMed PMID: 19033363; PubMed Central

1223 PMCID: PMCPMC2615629.

1224 70. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The

1225 GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Current

1226 protocols in bioinformatics. 2016;54(1):1.30.1-1..3. doi: 10.1002/cpbi.5.

1227





Figure 1






Figure 3




Figure 4




Figure 5




Figure 6




Figure 2